Page last updated: 2024-11-04

clofazimine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Clofazimine is an anti-inflammatory and antibacterial agent that is used to treat leprosy and other mycobacterial infections. Its synthesis involves a multi-step process starting with the condensation of 4-aminodiphenylamine with ethyl 4-chloro-3-nitrobenzoate. The compound is known for its unique mechanism of action that involves inhibiting the growth of bacteria by interfering with their cell wall synthesis and electron transport chain. Clofazimine has also shown promising results in treating various other diseases, including Crohn's disease, lupus, and certain types of cancer. Its anti-inflammatory properties make it an attractive candidate for the treatment of inflammatory bowel diseases. Furthermore, studies have demonstrated its efficacy against multidrug-resistant tuberculosis strains. Clofazimine is studied extensively due to its potential in treating a wide range of infectious diseases, including those caused by resistant bacterial strains. Its ability to target various aspects of bacterial metabolism makes it a valuable therapeutic option. Ongoing research focuses on further elucidating its mechanisms of action, optimizing its delivery systems, and exploring its potential for treating other conditions.'

Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2794
CHEMBL ID1292
CHEMBL ID1083384
CHEBI ID3749
SCHEMBL ID26758
SCHEMBL ID26757
SCHEMBL ID5663361
MeSH IDM0004579

Synonyms (169)

Synonym
BIDD:PXR0147
HMS3394B05
b 663 (pharmaceutical)
b 663, pharmaceutical
g 30320
lampren
b 663
nsc-141046
b-663
chlofazimine
phenazine,10-dihydro-3-(p-chloroanilino)-10-(p-chlorophenyl)-2-(isopropylimino)-
lamprene
nsc141046
phenazine,10-dihydro-2-(isopropylimino)-
3-(p-chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin
3-(p-chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine
3-(p-chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine
2-phenazinamine,5-dihydro-n,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-
2-phenazinamine,5-bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-
smr000058704
SMP2_000339 ,
(3z)-n,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine
clofazimina
g-30320
phenazine, 3-(p-chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-
clofaziminum [inn-latin]
clofazimina [inn-spanish]
3-(p-chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine
2-phenazinamine, n,5-bis(4-chlorophenyl)-3,5-dihydro-3-((1-methylethyl)imino)-
2-phenazinamine, 3,5-dihydro-n,5-bis(4-chlorophenyl)-3-((1-methylethyl)imino)-
einecs 217-980-2
b 663 (van)
brn 0060420
phenazine, 2,10-dihydro-3-(p-chloroanilino)-10-(p-chlorophenyl)-2-(isopropylimino)-
3-(p-chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [german]
nsc 141046
PRESTWICK_685
NCGC00016600-01
cas-2030-63-9
BSPBIO_000531
PRESTWICK3_000376
PRESTWICK2_000376
NCGC00179529-01
b. 663
(3e)-n,5-bis(4-chlorophenyl)-3-isopropylimino-phenazin-2-amine
n,5-bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine
b663
MLS001424318
clofazimine
C06915
2030-63-9
riminophenazine
cpd000058704 ,
DB00845
lamprene (tn)
D00278
clofazimine (jan/usp/inn)
BPBIO1_000585
MLS000028617
SPBIO_002452
PRESTWICK0_000376
PRESTWICK1_000376
NCGC00016600-02
HMS2093J10
HMS2052B05
CHEMBL1292
colfazimine
n,5-bis(4-chlorophenyl)-3-(isopropylimino)-3,5-dihydrophenazin-2-amine
(4-chloro-phenyl)-[5-(4-chloro-phenyl)-3-isopropylimino-3,5-dihydro-phenazin-2-yl]-amine
CHEBI:3749 ,
n,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine
clofaziminum
FT-0657414
HMS1569K13
CHEMBL1083384 ,
cid_2794
bdbm50318909
n,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine
ksc-27-052a
KUC109573N
HMS2096K13
d959ae5usf ,
clofazimine [usan:usp:inn:ban]
4-25-00-03033 (beilstein handbook reference)
unii-d959ae5usf
n,5-bis(4-chlorophenyl)-3-propan-2-ylimino-2-phenazinamine
n,5-bis(4-chlorophenyl)-3-propan-2-ylimino-phenazin-2-amine
A814428
pharmakon1600-01505974
nsc-759283
nsc759283
tox21_110516
dtxsid7022839 ,
dtxcid302839
HMS2231B04
S4107
CCG-101159
NCGC00016600-03
NCGC00016600-05
NCGC00016600-04
bdbm50378783
NCGC00016600-07
AKOS015896438
clofazimine [orange book]
clofazimine [usp impurity]
clofazimine [inn]
clofazimine [usan]
clofaziminum [who-ip latin]
colfazimine [vandf]
clofazimine [jan]
clofazimine [who-dd]
clofazimine [usp monograph]
clofazimine [ep monograph]
clofazimine [usp-rs]
clofazimine [vandf]
clofazimine [mart.]
clofazimine [mi]
clofazimine [who-ip]
HMS3370N05
smr004701474
MLS006010789
NC00409
SCHEMBL26758
SCHEMBL26757
CS-4567
SCHEMBL5663361
2-p-chloranilino-5-p-chlorphenyl-3,5-dihydro-3-isopropylimino-phenazin
n,5-bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine
n,5-bis(4-chlorophenyl)-3,5-dihydro-3-(isopropyliaino)phenazin-2-amine
KS-1412
2-phenazinamine, n,5-bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-
WDQPAMHFFCXSNU-KRUMMXJUSA-N
n,5-bis(4-chlorophenyl)-3-([1-methylethyl]imino)-3,5-dihydro-2-phenazinamine #
HY-B1046
C2866
mfcd00056793
gtpl9184
AKOS026749881
SR-05000001807-2
sr-05000001807
clofazimine, united states pharmacopeia (usp) reference standard
HMS3652A16
SR-05000001807-1
clofazimine, european pharmacopoeia (ep) reference standard
clofazimine for system suitability, european pharmacopoeia (ep) reference standard
Z2037279473
J-013203
SBI-0206865.P001
HMS3713K13
mmv687800
(e)-n,5-bis(4-chlorophenyl)-3-(isopropylimino)-3,5-dihydrophenazin-2-amine
SW196840-4
NCGC00016600-08
NCGC00016600-09
BCP07792
Q418611
AMY22515
BRD-K56614220-001-10-9
A16462
2-phenazinamine,n,5-bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-
CCG-269477
SR-01000000259-6
sr-01000000259
clofazimine 100 microg/ml in acetonitrile
n,5-bis(4-chlorophenyl)-3-[(propan-2-yl)imino]-3,5-dihydrophenazin-2-amine
EN300-267815
2458811-14-6
(3e)-n,5-bis(4-chlorophenyl)-3-[(propan-2-yl)imino]-3,5-dihydrophenazin-2-amine
EN300-21680301

Research Excerpts

Overview

Clofazimine (CFZ) is a weakly basic, Food and Drug Administration-approved antibiotic recommended by the World Health Organization to treat leprosy and multi-drug-resistant tuberculosis. It is a hydrophobic, anti-mycobacterial agent with virtually no detectable water solubility in its free base form.

ExcerptReferenceRelevance
"Clofazimine (CFZ) is an important component of the World Health Organization's (WHO) recommended all-oral drug regimen for treatment of multi-drug resistant tuberculosis (MDR-TB). "( Development of low-cost, weight-adjustable clofazimine mini-tablets for treatment of tuberculosis in pediatrics.
Brunaugh, A; Koleng, JJ; Martins, PP; Parekh, J; Smyth, HDC; Trementozzi, A; Warnken, Z, 2023
)
2.62
"Clofazimine is an anti-leprosy drug that is normally only prescribed for a few years."( Fatal course of clofazimine-induced pulmonary crystal deposition in a patient with Melkersson-Rosenthal syndrome.
Bittmann, I; Ganzert, C; Lücke, E; Schreiber, J; Wu, Q, 2020
)
1.63
"Clofazimine is an antimicrobial agent that has activity in vitro against mycobacteria. "( Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection.
Daley, CL; Levin, A; Martiniano, SL; Nick, JA; Sagel, SD; Wagner, BD, 2017
)
2.19
"Clofazimine is a weakly basic, Food and Drug Administration-approved antibiotic recommended by the World Health Organization to treat leprosy and multi-drug-resistant tuberculosis. "( The Physicochemical Basis of Clofazimine-Induced Skin Pigmentation.
Keswani, RK; LaLone, V; Larsen, S; Murashov, MD; Rajeswaran, W; Rosania, GR; Rzeczycki, PM; Stringer, KA; Sud, S; Yoon, GS, 2018
)
2.21
"Clofazimine is a hydrophobic, anti-mycobacterial agent with virtually no detectable water solubility in its free base form."( Investigating the effects of amphipathic gastrointestinal compounds on the solution behaviour of salt and free base forms of clofazimine: An in vitro evaluation.
Bannigan, P; Hudson, SP; Kumar, A; Madden, C; Stokes, K, 2018
)
1.41
"Clofazimine (CFZ) is a hydrophobic antibiotic agent which exhibits poor solubility. "( Delivery of a hydrophobic drug into the lower gastrointestinal system via an endogenous enzyme-mediated carrier mechanism: An in vitro study.
Bannigan, P; Durack, E; Hudson, SP; Mathur, H; Rea, MC; Ross, RP, 2018
)
1.92
"Clofazimine (CFZ) is an FDA-approved, poorly soluble small molecule drug that precipitates as crystal-like drug inclusions (CLDIs) which accumulate in acidic cytoplasmic organelles of macrophages. "( An Expandable Mechanopharmaceutical Device (1): Measuring the Cargo Capacity of Macrophages in a Living Organism.
Baik, J; Keswani, R; Murashov, MD; Rodriguez-Hornedo, N; Rosania, GR; Rzeczycki, P; Stringer, KA; Willmer, A; Woldemichael, T; Yoon, GS, 2018
)
1.92
"Clofazimine (CFZ) is a promising candidate drug for use in the management of multidrug-resistant tuberculosis (MDR-TB) patients. "( Synergistic activities of clofazimine with moxifloxacin or capreomycin against Mycobacterium tuberculosis in China.
Jiang, Y; Li, G; Li, M; Liu, H; Liu, Z; Wan, K; Wang, R; Xu, D; Xu, Z; Zhao, LL; Zhao, X, 2019
)
2.26
"Clofazimine (CLZ) is an effective antibiotic used against a wide spectrum of Gram-positive bacteria and leprosy. "( Single Crystal FLIM Characterization of Clofazimine Loaded in Silica-Based Mesoporous Materials and Zeolites.
Angiolini, L; Cohen, B; Douhal, A, 2019
)
2.22
"Clofazimine (CFZ) is a fat-soluble riminophenazine dye used in the treatment of leprosy worldwide."( Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.
Gopal, M; Metcalfe, JZ; O'Donnell, MR; Padayatchi, N, 2013
)
1.43
"Clofazimine (CLO) is a promising candidate drug for use in the management of multidrug-resistant tuberculosis (MDR-TB) patients. "( In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates.
Li, T; Pang, Y; Qu, G; Zhang, Z; Zhao, Y, 2015
)
2.14
"Clofazimine (CFZ) is an FDA-approved leprostatic and anti-inflammatory drug that massively accumulates in macrophages, forming insoluble, intracellular crystal-like drug inclusions (CLDIs) during long-term oral dosing. "( Phagocytosed Clofazimine Biocrystals Can Modulate Innate Immune Signaling by Inhibiting TNFα and Boosting IL-1RA Secretion.
Baik, J; Keswani, RK; Rosania, GR; Standiford, TJ; Stringer, KA; Sud, S; Yoon, GS, 2015
)
2.23
"Clofazimine (CZM) is an antileprosy drug that was recently repurposed for treatment of multidrug-resistant tuberculosis. "( Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against Mycobacterium tuberculosis.
Cole, ST; Lechartier, B, 2015
)
2.19
"Clofazimine (CFZ) is an optically active, red-colored chemotherapeutic agent that is FDA approved for the treatment of leprosy and is on the World Health Organization's list of essential medications. "( A far-red fluorescent probe for flow cytometry and image-based functional studies of xenobiotic sequestering macrophages.
Keswani, RK; Rosania, GR; Stringer, KA; Sud, S; Yoon, GS, 2015
)
1.86
"Clofazimine (CFZ) is a poorly soluble antibiotic and anti-inflammatory drug indicated for the treatment of leprosy. "( Clofazimine Biocrystal Accumulation in Macrophages Upregulates Interleukin 1 Receptor Antagonist Production To Induce a Systemic Anti-Inflammatory State.
Keswani, RK; Koehn, TA; Murashov, MD; Rosania, GR; Rzeczycki, PM; Standiford, TJ; Stringer, KA; Sud, S; Yoon, GS, 2016
)
3.32
"Clofazimine (CLF) is an FDA-approved leprostatic, anti-tuberculosis, and anti-inflammatory drug that was previously shown to have growth suppression effect on various cancer types such as hepatocellular, lung, cervix, esophageal, colon, and breast cancer as well as melanoma, neuroblastoma, and leukemia."( Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line.
Ataş, H; Biber, A; Durusu, İZ; Gerekçi, S; Güleç, EA; Hüsnügil, HH; Özen, C, 2017
)
1.49
"Clofazimine enterophathy is a serious complication of clofazimine when used at high doses for treatment of type 2 lepra or or erythema nodosum leprosum. "( [Persistent type 2 lepra reaction (erythema nodosum) and clofazimine-induced lethal enteropathy].
Gómez, Y; López, F; Pinto, R; Rodríguez, G, 2009
)
2.04
"Clofazimine is a riminophenazine compound which has been used for the treatment of leprosy since the 1960s. "( Apoptosis-inducing activity of clofazimine in macrophages.
Fukutomi, Y; Maeda, Y; Makino, M, 2011
)
2.1
"Clofazimine is a lipophilic antibiotic with an extremely long pharmacokinetic half-life associated with the appearance of crystal-like drug inclusions, in vivo. "( Molecular imaging of intracellular drug-membrane aggregate formation.
Baik, J; Rosania, GR, 2011
)
1.81
"Clofazimine is a poorly-soluble but orally-bioavailable small molecule drug that massively accumulates in macrophages when administered over prolonged periods of time. "( Macrophages sequester clofazimine in an intracellular liquid crystal-like supramolecular organization.
Baik, J; Rosania, GR, 2012
)
2.14
"Clofazimine is a potent anti-staphylococcal agent. "( Anti-staphylococcal activity and mode of action of clofazimine.
Chopra, I; Miller, K; O'Neill, AJ; Oliva, B; Stubbings, W, 2004
)
2.02
"Clofazimine is a drug used to treat leprosy."( How can we help patients with refractory chronic graft versus host disease- single centre experience.
Barzal, J; Oborska, S; Rzepecki, P; Sarosiek, T; Szczylik, C, 2007
)
1.06
"Clofazimine seems to be an effective treatment, although long-term application is necessary with frequent aggravation in the beginning."( Cheilitis granulomatosa and Melkersson-Rosenthal syndrome: evaluation of gastrointestinal involvement and therapeutic regimens in a series of 14 patients.
Ratzinger, G; Sepp, N; Tilg, H; Vogetseder, W, 2007
)
1.06
"Clofazimine is a valuable drug which is used worldwide in the treatment of leprosy. "( Clofazimine-induced ichthyosis and its treatment.
Caver, CV, 1982
)
3.15
"Clofazimine is a well known anti-leprosy drug; in addition, from the results obtained here, this drug could induce anti-M."( Clofazimine-mediated augmentation of LPS-induced tumor necrosis factor production in macrophages.
Fukutomi, Y; Minagawa, F; Xiong, JG, 1994
)
2.45
"Clofazimine (Lamprene) is an antimycobacterial drug that has antiinflammatory activity in a number of chronic autoimmune skin disorders. "( Treatment of chronic graft-versus-host disease with clofazimine.
Antin, JH; Bierer, BE; Lee, SJ; McGarigle, CJ; Wegner, SA, 1997
)
1.99
"Clofazimine is an important and effective constituent of multi drug therapy for leprosy. "( Excretion of clofazimine in human milk in leprosy patients.
Girdhar, A; Girdhar, BK; Mathur, A; Venkatesan, K, 1997
)
2.11
"Clofazimine was found to be a more potent scavenger of HOCl than dapsone when the inhibition of NADH oxidation by reagent HOCl was used as an assay."( Mechanisms by which clofazimine and dapsone inhibit the myeloperoxidase system. A possible correlation with their anti-inflammatory properties.
Basson, K; Kriegler, A; van der Walt, BJ; van Zyl, JM, 1991
)
1.33

Effects

Clofazimine has been regarded as a promising agent for the treatment of nontuberculous mycobacteria pulmonary disease (NTM-PD) The drug has shown activity against Mycobacterium tuberculosis, including multidrug-resistant (MDR) st.

ExcerptReferenceRelevance
"Clofazimine has a long history of use and has demonstrated a good safety profile for a disease that requires chronic dosing for a period of time ranging 3-36 months."( A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.
Beasley, FC; Chatterjee, AK; Huston, CD; Jumani, RS; Love, MS; McNamara, CW; Schultz, PG; Wright, TM, 2017
)
1.43
"Clofazimine (CFZ) has showed benefit in shortening DS-TB treatment in vivo from six to four months when used in combination with this regimen in murine models of experimental infection."( Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro.
Anderson, R; Cholo, MC; Mashele, SA; Matjokotja, MT; Rasehlo, SSM; Steel, HC, 2022
)
1.73
"Clofazimine (CFZ) has attracted attention due to its anti-inflammatory property in immune diseases as well as infectious diseases."( Proteomic analysis and identification reveal the anti-inflammatory mechanism of clofazimine on lipopolysaccharide-induced acute lung injury in mice.
Feng, FK; Gao, Z; Ji, LL; Li, QS; Li, W; Li, XP; Song, L; Wang, GS; Wang, R; Wang, XY; Wang, YN; Xie, H; Xu, HL; Yang, B; Zhang, XY, 2022
)
1.67
"Clofazimine has been regarded as a promising agent for the treatment of nontuberculous mycobacteria pulmonary disease (NTM-PD). "( Minimal Inhibitory Concentration of Clofazimine Among Clinical Isolates of Nontuberculous Mycobacteria and Its Impact on Treatment Outcome.
Kim, SA; Kim, TS; Kwak, N; Whang, J; Yang, JS; Yim, JJ, 2021
)
2.34
"Clofazimine has excellent in vitro activity against M abscessus, but reports of its use, particularly in children, have been limited."( Safety and Tolerability of Clofazimine in a Cohort of Children With Odontogenic Mycobacterium abscessus Infection.
Adler-Shohet, FC; Arrieta, A; Ashouri, N; Flores, MC; Nieves, D; Singh, J; Tran, MT, 2020
)
1.58
"Clofazimine has shown activity in vitro against Mycobacterium tuberculosis, but clinical experience with clofazimine in XDR-TB and HIV coinfection is limited."( Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study.
Gopal, M; Master, I; Naidoo, K; Naidoo, R; O'Donnell, MR; Padayatchi, N; Werner, L, 2014
)
2.57
"Clofazimine (Cfz) has shown activity against Mycobacterium tuberculosis, including multidrug-resistant (MDR) strains in vitro and in animal studies. "( Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China.
Gu, J; Hao, X; Li, F; Li, M; Liu, G; Liu, Y; Sun, H; Tang, S; Wang, X; Wu, M; Yao, L; Zeng, L; Zhang, Z; Zhu, Y, 2015
)
3.3
"Clofazimine has a long history of use and has demonstrated a good safety profile for a disease that requires chronic dosing for a period of time ranging 3-36 months."( A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.
Beasley, FC; Chatterjee, AK; Huston, CD; Jumani, RS; Love, MS; McNamara, CW; Schultz, PG; Wright, TM, 2017
)
1.43
"Clofazimine (CLF) has been included as an essential component of MDT, which is the standard WHO regimen for treatment of leprosy."( Does clofazimine (B663) reach Mycobacterium leprae persisting in Schwann cells and endothelial cells of endoneurial blood vessels in peripheral nerves?
Kumar, V, 2008
)
1.58
"Clofazimine has in vitro and in vivo activities against M. "( [Activities of clofazimine against Mycobacterium tuberculosis in vitro and in vivo].
Chu, NH; Li, P; Liang, BW; Lu, Y; Wang, B; Zhao, WJ; Zheng, MQ, 2008
)
2.14
"Clofazimine has shown activity against Mycobacterium tuberculosis, including multidrug-resistant strains in vitro and in animal studies. "( Clofazimine in the treatment of multidrug-resistant tuberculosis.
Jiang, RH; Xiao, HP; Xu, HB, 2012
)
3.26
"Clofazimine has been shown to have anti-staphylococcal activity. "( Antimicrobial activities of seven novel tetramethylpiperidine-substituted phenazines against multiple-drug-resistant Gram-positive bacteria.
Huygens, F; O'Sullivan, JF; van Rensburg, CE, 2005
)
1.77
"Clofazimine has been in clinical use for almost 40 years, but little is known of its mechanism of action. "( Clofazimine: a review of its medical uses and mechanisms of action.
Arbiser, JL; Moschella, SL, 1995
)
3.18

Actions

The clofazimine MIC50 to inhibit isolate growth was approximately 3.3 μg/mL for both strains. Clofazamine did not cause change in the pharmacokinetics of dapsone.

ExcerptReferenceRelevance
"The clofazimine MIC50 to inhibit isolate growth was approximately 3.3 μg/mL for both strains."( In vitro interaction of some drug combinations to inhibit rapidly growing mycobacteria isolates from cats and dogs and these isolates' susceptibility to cefovecin and clofazimine.
Bennie, CJ; Govendir, M; Martin, PA; To, JL,
)
0.81
"Clofazimine did not cause change in the pharmacokinetics of dapsone."( Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria.
Pieters, FA; Woonink, F; Zuidema, J, 1988
)
1.25

Treatment

In clofazimine-treated mice, skin cryosections revealed no evidence of CLDIs when analyzed with a microscopic imaging system specifically designed for detecting clofAZimine aggregates. Clofazamine treatment was superior to prednisolone (more treatment successes; RR 3.67; 95% CI 136 to 9.91) and thalidomide.

ExcerptReferenceRelevance
"In clofazimine-treated mice, skin cryosections revealed no evidence of CLDIs when analyzed with a microscopic imaging system specifically designed for detecting clofazimine aggregates."( The Physicochemical Basis of Clofazimine-Induced Skin Pigmentation.
Keswani, RK; LaLone, V; Larsen, S; Murashov, MD; Rajeswaran, W; Rosania, GR; Rzeczycki, PM; Stringer, KA; Sud, S; Yoon, GS, 2018
)
1.29
"Clofazimine treatment was superior to prednisolone (more treatment successes; RR 3.67; 95% CI 1.36 to 9.91) (1 trial, 24 participants), and thalidomide (fewer recurrences; RR 0.08; 95% CI 0.01 to 0.56) (1 trial, 72 participants)."( Interventions for erythema nodosum leprosum.
Lockwood, DN; Ramirez, J; Richardus, JH; van Brakel, WH; Van Veen, NH, 2009
)
1.07
"Clofazimine treatment was superior to prednisolone (more treatment successes; RR 3.67; 95% CI 136 to 9.91) and thalidomide (fewer recurrences; RR 0.08; 95% CI 0.01, 0-56)."( Interventions for erythema nodosum leprosum. A Cochrane review.
Lockwood, DN; Ramirez, J; Richardus, JH; Van Brakel, WH; Van Veen, NH, 2009
)
1.07
"Clofazimine treatment resulted in total remission."( Cutaneous malakoplakia. Report of a case.
Baradad, M; Bombí, JA; Martín, E; Mascaró, JM; Palou, J; Torras, H, 1988
)
1
"Clofazimine treatment over a period of one year in patients with suspected DDS resistance and repeated attacks of lepra reaction decreased total LDH activity and M/H ratio considerably."( L.D.H. isoenzymes sub-unit ratio in leprosy and the effect of clofazimine treatment on L.D.H. isoenzymes sub-unit.
Bulakh, PM; Burte, NP; Chandorkar, AG; Kowale, CN; Ranade, SM,
)
1.09
"Treatment with clofazimine alone, clofazimine plus azithromycin, and atovaquone plus azithromycin was ineffective and failed to eliminate the parasites completely, while a 44-day treatment with clofazimine plus atovaquone was highly effective and resulted in a radical cure."( Combination of Clofazimine and Atovaquone as a Potent Therapeutic Regimen for the Radical Cure of Babesia microti Infection in Immunocompromised Hosts.
Ahedor, B; Batmagnai, E; Igarashi, I; Liu, M; Nugraha, AB; Otgonsuren, D; Sivakumar, T; Tuvshintulga, B; Xuan, X; Yokoyama, N, 2022
)
1.41
"Mice treated with clofazimine were culture-negative after 5 months, whereas all mice treated without clofazimine remained heavily culture-positive for the entire 9 months of the study."( Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.
Almeida, DV; Ammerman, NC; Bishai, WR; Converse, PJ; Enarson, D; Grosset, JH; Li, SY; Trébucq, A; Tyagi, S, 2013
)
1.07
"Treatment with clofazimine (100 mg 4 times weekly for 3-11 months) was associated with complete remission in 5/10 patients and clinical improvement in 3/10 patients with moderate constant swelling."( Melkersson-Rosenthal syndrome: clinical, pathologic, and therapeutic considerations.
Steinberg, S; Sussman, GL; Yang, WH, 1992
)
0.62
"Treatment with clofazimine dramatically improved swelling of the lips."( [Melkersson-Rosenthal syndrome. A case treated with clofazimine].
Cusano, F; Errico, A; Errico, G; Lamparelli, A, 1991
)
0.87
"Treatment with clofazimine resulted in a marked improvement of the lesions."( Malignant pyoderma. Report of a case associated with a disorder of the immune system.
Aram, H, 1985
)
0.61

Toxicity

Clofazimine (CFZ) is used to treat pulmonary non-tuberculous mycobacterial (NTM) infection. Its pharmacokinetics remain unexplored in patients with pulmonary NTM, and the relationship between CFZ serum concentration and adverse effects has not been investigated. The most common adverse event from clofazemine was skin discoloration, in 60% of patients.

ExcerptReferenceRelevance
" The common side effect in all cases consisted of red and dark skin pigmentation of varying intensity occuring within 10 weeks of the commencement of therapy."( Side effects of clofazimine therapy.
Iyer, GG; Ramu, G, 1976
)
0.6
" It appears that this side effect has never been reported in the literature."( Lamprene (clofazimine) and its side effects.
Kharkar, RD; Salafia, A,
)
0.53
" It is concluded that the combination RMP + ETH is the toxic component."( Hepatotoxicity of the combination of rifampin-ethionamide in the treatment of multibacillary leprosy.
Bourland, J; Davies, EM; Feracci, C; Grillone, S; Janssens, L; Pattyn, SR; Saylan, T, 1984
)
0.27
" The present studies with both erythrocytes and macrophages as the model systems show that liposomal drug is far less toxic in vitro than the free drug."( Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection.
Mehta, RT, 1996
)
0.59
" We conclude that CFZ is a generally well tolerated and safe drug when given as a daily dose of 50mg, which is currently used in leprosy patients."( Biochemical and hematological side effects of clofazimine in leprosy patients.
Costa Queiroz, RH; de Souza, AM; Melchior, E; Sampaio, SV, 2002
)
0.57
"The introduction of multidrug therapy (WHO/MDT)-composed by the drugs dapsone, clofazimine and rifampicin has enabled the cure of Hansen's disease, however, the adverse effects of these drugs were not given priority by the health team."( [Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlândia].
Arbex, GL; Carneiro, MH; Gadia, R; Goulart, IM; Rodrigues, MS,
)
0.36
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" DHS and other adverse effects of dapsone lead to withdrawal of the drug."( A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
Pandey, B; Sapkota, BR; Shrestha, K; Walker, SL, 2008
)
0.35
"We reviewed the notes of patients who had dapsone withdrawn from their multi-drug therapy (MDT) following an adverse reaction to the drug between 1990 and 2007."( A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
Pandey, B; Sapkota, BR; Shrestha, K; Walker, SL, 2008
)
0.35
"Rifampicin and clofazimine appear to be satisfactory treatment for both paucibacillary and multibacillary patients who have to have dapsone stopped because of severe adverse effects."( A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
Pandey, B; Sapkota, BR; Shrestha, K; Walker, SL, 2008
)
0.7
"To assess the adverse effects of multi drug therapy (MDT) in leprosy patients."( Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur).
Dey, V; Dulhani, N; Nel, B; Singh, H; Tiwari, P, 2011
)
0.37
" The adverse effects were recorded on the personal record of every individual patient, filled during the course of treatment."( Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur).
Dey, V; Dulhani, N; Nel, B; Singh, H; Tiwari, P, 2011
)
0.37
"176 patient's records were analysed, looking for adverse effects."( Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur).
Dey, V; Dulhani, N; Nel, B; Singh, H; Tiwari, P, 2011
)
0.37
"This study sought to verify the correlation between leprosy types and the adverse effects of treatment drugs."( Brazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effects.
Almeida, PC; Bührer-Sékula, S; Cruz, R; Gonçalves, Hde S; Moraes, ME; Penna, GO; Pontes, MA, 2012
)
0.38
" Hence, new alternative schemes and monitoring of adverse effects to avoid treatment abandonment are important considerations."( Adverse effects of alternative therapy (minocycline, ofloxacin, and clofazimine) in multibacillary leprosy patients in a recognized health care unit in Manaus, Amazonas, Brazil.
Cunha, CS; Cunha, Mda G; Maia, MV,
)
0.37
" The mean time for the development of adverse effects after beginning the therapy was 15."( Adverse effects of alternative therapy (minocycline, ofloxacin, and clofazimine) in multibacillary leprosy patients in a recognized health care unit in Manaus, Amazonas, Brazil.
Cunha, CS; Cunha, Mda G; Maia, MV,
)
0.37
"While the data were limited, Cfz was associated with a risk for adverse drug reactions comparable to that of first-line TB treatment, which could be reasonably managed under programmatic conditions."( Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies.
Dotsenko, S; Falzon, D; Hwang, TJ; Jafarov, A; Jaramillo, E; Keshavjee, S; Lunte, K; Nunn, P; Wares, DF; Weyer, K, 2014
)
0.7
" The most common adverse event from clofazimine was skin discoloration, in 60% of patients."( Safety and tolerability of clofazimine as salvage therapy for atypical mycobacterial infection in solid organ transplant recipients.
Abdel-Massih, RC; Cariello, PF; Kwak, EJ; Silveira, FP, 2015
)
0.99
"Clofazimine appears safe and may be considered as a salvage therapeutic option in SOT recipients with MAC infection who are intolerant or unresponsive to standard therapy."( Safety and tolerability of clofazimine as salvage therapy for atypical mycobacterial infection in solid organ transplant recipients.
Abdel-Massih, RC; Cariello, PF; Kwak, EJ; Silveira, FP, 2015
)
2.16
"Type 2 lepra reaction (T2R) is a difficult-to-manage condition in leprosy, and an effective and safe steroid-sparing agent is needed for its management."( Effectiveness and safety of clofazimine and pentoxifylline in type 2 lepra reaction: a double-blind, randomized, controlled study.
Bandyopadhyay, D; Das, NK; Roy, K; Sil, A, 2015
)
0.71
" Safety parameters were spontaneously appearing adverse events and laboratory parameter changes."( Effectiveness and safety of clofazimine and pentoxifylline in type 2 lepra reaction: a double-blind, randomized, controlled study.
Bandyopadhyay, D; Das, NK; Roy, K; Sil, A, 2015
)
0.71
" Treatment regimens and adverse drug reactions (ADRs) were captured."( Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection.
Daley, CL; Levin, A; Martiniano, SL; Nick, JA; Sagel, SD; Wagner, BD, 2017
)
0.75
"The Clinical Trial for Uniform Multidrug Therapy for Leprosy Patients in Brazil (U-MDT/CT-BR), designed to evaluate the effectiveness of a six-months regimen, assessed the adverse effects caused by the drugs."( Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
Bührer-Sékula, S; Cruz, RCDS; Gonçalves, HS; Moraes, MEA; Penna, GO; Penna, MLF; Pontes, MAA; Stefani, MMA; Talhari, S, 2018
)
0.48
"Describe adverse effects due to MDT in U-MDT/CT-BR, comparing the uniform regimen (U-MDT) to the current WHO regimen (R-MDT)."( Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
Bührer-Sékula, S; Cruz, RCDS; Gonçalves, HS; Moraes, MEA; Penna, GO; Penna, MLF; Pontes, MAA; Stefani, MMA; Talhari, S, 2018
)
0.48
"2%) stopped dapsone intake due to adverse effects, of whom 16."( Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
Bührer-Sékula, S; Cruz, RCDS; Gonçalves, HS; Moraes, MEA; Penna, GO; Penna, MLF; Pontes, MAA; Stefani, MMA; Talhari, S, 2018
)
0.48
"There was no statistical difference regarding adverse effects in the R-MDT and U-MDT groups but anemia was greater in patients from R-MDT/MB group, therefore adverse effects do not represent a constraint to recommend the six-month uniform regimen of treatment for all leprosy patients."( Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
Bührer-Sékula, S; Cruz, RCDS; Gonçalves, HS; Moraes, MEA; Penna, GO; Penna, MLF; Pontes, MAA; Stefani, MMA; Talhari, S, 2018
)
0.48
" Patients were followed up for sputum smear and culture conversion and adverse events during the treatment."( Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis.
Khalid, UK; Mathuria, KK; Munjal, SK; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Verma, A; Vohra, V, 2019
)
0.51
" 29 adverse events (AE) were reported among 17 patients and there were 11 deaths."( Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis.
Khalid, UK; Mathuria, KK; Munjal, SK; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Verma, A; Vohra, V, 2019
)
0.51
"BDQ and DLM given together in a salvage regimen is efficacious with low rate of adverse events."( Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis.
Khalid, UK; Mathuria, KK; Munjal, SK; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Verma, A; Vohra, V, 2019
)
0.51
"To report on dose-related adverse events in patients receiving CFZ plus a background regimen for DR TB."( Dose-related adverse events in South African patients prescribed clofazimine for drug-resistant tuberculosis.
Misra, N; Naidoo, P; Padayatchi, N, 2019
)
0.75
"In a retrospective review of patient folders from 2012 to 2014, adverse events documented for patients receiving high- (≥200 mg) and low-dose (100 mg) CFZ in a centralised DR TB hospital in KwaZulu-Natal Province, SA, were investigated for an association between dose-weight interactions and adverse events."( Dose-related adverse events in South African patients prescribed clofazimine for drug-resistant tuberculosis.
Misra, N; Naidoo, P; Padayatchi, N, 2019
)
0.75
" The frequency and types of adverse events observed were similar to the published literature."( Dose-related adverse events in South African patients prescribed clofazimine for drug-resistant tuberculosis.
Misra, N; Naidoo, P; Padayatchi, N, 2019
)
0.75
"There is an association between dose-weight interaction and adverse events."( Dose-related adverse events in South African patients prescribed clofazimine for drug-resistant tuberculosis.
Misra, N; Naidoo, P; Padayatchi, N, 2019
)
0.75
" These drugs are associated with numerous adverse events that can cause severe morbidity, such as deafness, and in some instances can lead to death."( Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Ahmad, N; Baghaei, P; Barkane, L; Benedetti, A; Brode, SK; Brust, JCM; Campbell, JR; Chang, VWL; Falzon, D; Guglielmetti, L; Isaakidis, P; Kempker, RR; Kipiani, M; Kuksa, L; Lan, Z; Lange, C; Laniado-Laborín, R; Menzies, D; Nahid, P; Rodrigues, D; Singla, R; Udwadia, ZF, 2020
)
0.56
"We did a meta-analysis using individual-level patient data that were obtained from studies that reported adverse events that resulted in permanent discontinuation of anti-tuberculosis medications."( Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Ahmad, N; Baghaei, P; Barkane, L; Benedetti, A; Brode, SK; Brust, JCM; Campbell, JR; Chang, VWL; Falzon, D; Guglielmetti, L; Isaakidis, P; Kempker, RR; Kipiani, M; Kuksa, L; Lan, Z; Lange, C; Laniado-Laborín, R; Menzies, D; Nahid, P; Rodrigues, D; Singla, R; Udwadia, ZF, 2020
)
0.56
" Using meta-analysis of proportions, drugs with low risks of adverse event occurrence leading to permanent discontinuation included levofloxacin (1·3% [95% CI 0·3-5·0]), moxifloxacin (2·9% [1·6-5·0]), bedaquiline (1·7% [0·7-4·2]), and clofazimine (1·6% [0·5-5·3])."( Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Ahmad, N; Baghaei, P; Barkane, L; Benedetti, A; Brode, SK; Brust, JCM; Campbell, JR; Chang, VWL; Falzon, D; Guglielmetti, L; Isaakidis, P; Kempker, RR; Kipiani, M; Kuksa, L; Lan, Z; Lange, C; Laniado-Laborín, R; Menzies, D; Nahid, P; Rodrigues, D; Singla, R; Udwadia, ZF, 2020
)
0.74
"Fluoroquinolones, clofazimine, and bedaquiline had the lowest incidence of adverse events leading to permanent drug discontinuation, whereas second-line injectable drugs, aminosalicylic acid, and linezolid had the highest incidence."( Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Ahmad, N; Baghaei, P; Barkane, L; Benedetti, A; Brode, SK; Brust, JCM; Campbell, JR; Chang, VWL; Falzon, D; Guglielmetti, L; Isaakidis, P; Kempker, RR; Kipiani, M; Kuksa, L; Lan, Z; Lange, C; Laniado-Laborín, R; Menzies, D; Nahid, P; Rodrigues, D; Singla, R; Udwadia, ZF, 2020
)
0.89
" The aim was to describe the adverse effects of polychemotherapy, as well the most prevalent and most vulnerable populations."( Adverse effects of polychemotherapy for leprosy in 13 years of follow-up at a university hospital.
Brotas, AM; Carneiro, S; Daxbacher, EL; Tortelly, VD,
)
0.13
" The majority of these patients become steroid-dependent and suffer from the adverse effects of long-term corticosteroid use."( Comparison of the efficacy and safety of minocycline and clofazimine in chronic and recurrent erythema nodosum leprosum-A randomized clinical trial.
Dogra, S; Hanumanthu, V; Narang, T; Thakur, V, 2021
)
0.87
" All serious adverse events and adverse events of special interest (AESI), leading to a treatment change, or judged significant by a clinician, were systematically monitored and documented."( Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
Ahmed, S; Bastard, M; Franke, MF; Grium Tefera, D; Hewison, C; Holtzman, D; Huerga, H; Islam, S; Jacques Leblanc, G; Khan, PY; Khan, U; Kumsa, A; Lachenal, N; Leonovich, O; Mamsa, S; Manzur-Ul-Alam, M; Melikyan, N; Mitnick, CD; Myint, Z; Osso, E; Padayachee, S; Rafi Siddiqui, M; Rashitov, M; Rich, ML; Salahuddin, N; Salia, G; Sánchez, E; Serobyan, A; Seung, KJ; Varaine, F; Vetushko, D; Yeghiazaryan, L, 2022
)
0.72
"Concomitant use of Bdq and Dlm, along with linezolid and clofazimine, is safe and effective for MDR/RR-TB patients with extensive disease."( Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
Ahmed, S; Bastard, M; Franke, MF; Grium Tefera, D; Hewison, C; Holtzman, D; Huerga, H; Islam, S; Jacques Leblanc, G; Khan, PY; Khan, U; Kumsa, A; Lachenal, N; Leonovich, O; Mamsa, S; Manzur-Ul-Alam, M; Melikyan, N; Mitnick, CD; Myint, Z; Osso, E; Padayachee, S; Rafi Siddiqui, M; Rashitov, M; Rich, ML; Salahuddin, N; Salia, G; Sánchez, E; Serobyan, A; Seung, KJ; Varaine, F; Vetushko, D; Yeghiazaryan, L, 2022
)
0.97
"Clofazimine (CFZ) is used to treat pulmonary non-tuberculous mycobacterial (NTM) infection; however, its pharmacokinetics remain unexplored in patients with pulmonary NTM, and the relationship between CFZ serum concentration and adverse effects has not been investigated."( Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infection.
Fujiwara, K; Furuuchi, K; Hanada, K; Hiramatsu, M; Kurashima, A; Morimoto, K; Ohta, K; Shiraishi, Y; Uesugi, F; Watanabe, F; Yoshiyama, T, 2022
)
2.43

Pharmacokinetics

ExcerptReferenceRelevance
" The elimination half-life is variable, with values as long as 70 days being quoted in the literature."( Clinical pharmacokinetics of clofazimine. A review.
Holdiness, MR, 1989
)
0.57
" Three days after rifampicin the elimination half-life of dapsone was reduced from 40."( Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria.
Pieters, FA; Woonink, F; Zuidema, J, 1988
)
0.53
" The mean terminal half-life was 10."( Pharmacokinetics of clofazimine in healthy volunteers.
Dieterle, W; Dubois, JP; Schaad-Lanyi, Z; Theobald, W; Vischer, W, 1987
)
0.6
"A comparative pharmacokinetic study of Lositril (rifampicin) was carried out in six multibacillary and twelve paucibacillary leprosy cases."( Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases.
Gandhi, IS; Mehta, J; Sane, SB; Wamburkar, MN,
)
0.53
"To determine the effect of a high-fat meal, orange juice, and antacids on absorption of a single oral dose of cycloserine and to estimate its population pharmacokinetic parameters."( Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids.
Adam, RD; Childs, JM; Nix, DE; Peloquin, CA; Zhu, M, 2001
)
0.31
" No other statistically significant differences were observed for Cmax and area under the curve from time zero to infinity across the four treatments."( Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids.
Adam, RD; Childs, JM; Nix, DE; Peloquin, CA; Zhu, M, 2001
)
0.31
" Pharmacokinetic parameters were evaluated in infected and uninfected BALB/c mice."( Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis.
Adamson, J; Almeida, DV; Ammerman, NC; Bester, LA; Dorasamy, A; Grosset, JH; Mgaga, Z; Moodley, C; Moodley, S; Ngcobo, B; Singh, S; Swanson, RV; Tapley, A, 2015
)
0.68
" As CFZ is an inhibitor of the cytochrome P450 isoenzyme 3A4 (CYP3A4) in vitro, and BDQ a substrate of CYP3A4, there is a potential for pharmacokinetic (PK) drug-drug interaction that may result in increased BDQ exposure when co-administered with CFZ, which could increase the toxicity of BDQ."( Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis.
Brill, MJE; Maartens, G; Pandie, M; Svensson, EM, 2018
)
0.73
" Primary endpoints include reduction in the number of Cryptosporidium shed in stools over a 5-day period and compared to placebo recipients and the PK of CFZ in plasma assessed by area under the curve, peak plasma concentration, and half-life (T ½) determined after the last dose."( Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial.
Gordon, MA; Hermann, D; Iroh Tam, PY; Nachipo, P; Quinnan, G; Van Voorhis, WC, 2018
)
0.71
" Pharmacokinetic data from relevant patient populations are needed to inform dose optimization."( Clofazimine pharmacokinetics in patients with TB: dosing implications.
Abdelwahab, MT; Brust, JCM; Dawson, R; Denti, P; Diacon, A; Everitt, D; Gandhi, NR; Maartens, G; Meintjes, G; Svensson, EM; Wasserman, S; Wiesner, L, 2020
)
2
"Clinical and pharmacokinetic data were obtained from participants with pulmonary TB enrolled in two studies with intensive and sparse sampling for up to 6 months."( Clofazimine pharmacokinetics in patients with TB: dosing implications.
Abdelwahab, MT; Brust, JCM; Dawson, R; Denti, P; Diacon, A; Everitt, D; Gandhi, NR; Maartens, G; Meintjes, G; Svensson, EM; Wasserman, S; Wiesner, L, 2020
)
2
"To help fill existing knowledge gaps, we evaluated the pharmacokinetic parameters of novel and repurposed anti-tuberculosis drugs among patients with drug-resistant pulmonary tuberculosis."( Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis.
Al-Shaer, MH; Alghamdi, WA; Barbakadze, K; Kempker, RR; Kipiani, M; Mikiashvili, L; Peloquin, CA, 2021
)
0.88

Compound-Compound Interactions

Clofazimine (CFZ) showed benefit in shortening DS-TB treatment in vivo from six to four months when used in combination with this regimen in murine models of experimental infection.

ExcerptReferenceRelevance
"The activity of TLC G-65 (a liposomal gentamicin preparation), alone and in combination with rifapentine, clarithromycin, clofazimine and ethambutol, was evaluated in the beige mouse (C57BL/6J--bgj/bgj) model of disseminated Mycobacterium avium infection."( TLC G-65 in combination with other agents in the therapy of Mycobacterium avium infection in beige mice.
Cynamon, MH; Klemens, SP; Swenson, CE, 1992
)
0.49
"Therapeutic efficacy of kanamycin (KM) and clofazimine (CFZ) combined with N2-[(N-acetyl-muramyl)-L-alanyl-D-isoglutaminyl]-N6-stearoyl-L-ly sine, MDP-Lys (L18), against Mycobacterium intracellulare infection induced in mice was studied, based on suppression of incidence of gross lung lesions and bacterial growth at the sites of infection (lungs and spleen), and the following results were obtained."( [Therapeutic efficacy of kanamycin and clofazimine combined with muramyl dipeptide against Mycobacterium intracellulare infection induced in mice].
Saito, H; Sato, K; Tomioka, H, 1991
)
0.81
" When clarithromycin was tested against three MAC strains in combination with another drug, it showed a synergistic effect only when combined with rifampicin."( In vitro activity of clarithromycin alone or in combination with other antimicrobial agents against Mycobacterium avium-intracellulare. Complex strains isolated from AIDS patients.
De Gregoris, P; Fattorini, L; Hu, CQ; Iona, E; Mascellino, MT; Orefici, G; Santoro, C, 1991
)
0.28
"The in vivo activity of amikacin, used alone or in combination with rifabutin or clofazimine or both, was assessed in the treatment of early and established Mycobacterium avium complex infections in beige mice."( In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice.
Gangadharam, PR; Iseman, MD; Kesavalu, L; Perumal, VK; Podapati, NR, 1988
)
0.75
" If chemotherapy is initiated 3 wk after challenge (established infections), the activity of this double drug combination is less effective."( Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections.
Farhi, DC; Gangadharam, PR; Iseman, MD; Jairam, BT; Nguyen, AK; Perumal, VK; Rao, PN, 1987
)
0.52
" Its optimal dosage appears to be 400 mg daily, and combination with dapsone and clofazimine does not enhance its activity."( Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy.
Grosset, JH; Ji, B; N'Deli, L; Perani, EG; Petinom, C, 1994
)
0.75
"In this study, the in vitro and in vivo anti-Mycobacterium leprae activity of the newly developed benzoxazinorifamycin, KRM-1648, in combination with clofazimine (CFZ) or dapsone (DDS) was evaluated."( Therapeutic efficacy of benzoxazinorifamycin, KRM-1648, in combination with other antimicrobials against Mycobacterium leprae infection induced in nude mice.
Dekio, S; Saito, H; Sato, K; Tomioka, H, 1994
)
0.49
"We have investigated the effects of cyclosporin A (CsA, 3-50 ng/ml) in combination with the riminophenazine agents clofazimine and B669 (60-500 ng/ml) on the mitogen- and alloantigen-activated proliferative responses of human mononuclear leukocytes (MNL), as well as on the phospholipase A2 and Na+, K+- adenosine triphosphatase activities of these cells."( Augmentative inhibition of lymphocyte proliferation by cyclosporin A combined with the riminophenazine compounds clofazimine and B669.
Anderson, R; Prinsloo, Y; van der Walt, R; van Rensburg, CE, 1995
)
0.71
"In the present study, we evaluated the in vivo anti-Mycobacterium leprae activities of KRM-1648 (KRM) given at long intervals in combination with ofloxacin (OFLX), clofazimine (CFZ), and dapsone (DDS)."( Studies on therapeutic activity of benzoxazinorifamycin KRM-1648 in combination with other antimicrobial agents and biological response modifiers interferon-gamma and granulocyte-macrophage colony-stimulating factor against M. leprae infection in athymic
Maw, WW; Saito, H; Sato, K; Tomioka, H, 1997
)
0.49
"To investigate whether selected drug combinations used to treat rapidly growing mycobacteria (RGM) have drug-drug interactions that affect efficacy and to investigate each isolate's susceptibility to cefovecin and clofazimine, individually."( In vitro interaction of some drug combinations to inhibit rapidly growing mycobacteria isolates from cats and dogs and these isolates' susceptibility to cefovecin and clofazimine.
Bennie, CJ; Govendir, M; Martin, PA; To, JL,
)
0.51
"We explored the potential synergistic effect of bedaquiline (BDQ) combined with moxifloxacin (MFX), gatifloxacin (GAT), clofazimine (CLO), and linezolid (LZD) for treatment of extensively drug-resistant tuberculosis (XDR-TB)."( No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis.
Chu, N; Dai, G; Dong, L; Huang, H; Huo, F; Jing, W; Li, Y; Lu, J; Pang, Y; Zong, Z, 2019
)
0.94
"Our in vitro data demonstrate no observed synergistic effects against XDR-TB for drug combinations that included BDQ in combination with MFX, GAT, LZD, or CLO."( No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis.
Chu, N; Dai, G; Dong, L; Huang, H; Huo, F; Jing, W; Li, Y; Lu, J; Pang, Y; Zong, Z, 2019
)
0.73
"In this case report the potential drug-drug interaction between cytochrome P450 (CYP) 3A4 substrates tezacaftor-ivacaftor and CYP3A4/5 inhibitor clofazimine is investigated in a patient with cystic fibrosis."( No drug-drug interaction between tezacaftor-ivacaftor and clofazimine: A case report.
Kemper, EM; Mathôt, RAA; Mouissie, LM; Terheggen-Lagro, SWJ; Vonk, SEM, 2022
)
1.17
" The results of our Greco universal response surface analysis showed that CFZ was at least additive with a clear trend towards synergy when combined with PMD, BDQ and LZD against Mtb in all explored metabolic states under in vitro checkerboard assay conditions."( Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
Almoslem, M; Drusano, GL; Duncanson, B; Kim, S; Louie, A; Myrick, J; Neely, M; Nole, J; Peloquin, CA; Scanga, CA; Schmidt, S; Yamada, W, 2022
)
1.02
" Clofazimine (CFZ) has showed benefit in shortening DS-TB treatment in vivo from six to four months when used in combination with this regimen in murine models of experimental infection."( Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro.
Anderson, R; Cholo, MC; Mashele, SA; Matjokotja, MT; Rasehlo, SSM; Steel, HC, 2022
)
1.92
"In the current in vitro study, the inhibitory and bactericidal activities of CFZ in combination with the primary anti-TB drugs, RMP, INH and EMB against the AR and SR organisms in planktonic and biofilm-forming cultures, respectively, were evaluated by fractional inhibitory concentration index (FICI) and fractional bactericidal concentration index (FBCI) determinations, using the Loewe Additivity Model."( Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro.
Anderson, R; Cholo, MC; Mashele, SA; Matjokotja, MT; Rasehlo, SSM; Steel, HC, 2022
)
1.01
"In planktonic cultures, CFZ demonstrated synergistic growth inhibitory activity in combination with RMP and INH individually and collectively."( Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro.
Anderson, R; Cholo, MC; Mashele, SA; Matjokotja, MT; Rasehlo, SSM; Steel, HC, 2022
)
1.01
"Clofazimine exhibited synergistic effects in combination with primary anti-TB drugs against both planktonic and biofilm-forming cultures, showing potential benefit in augmenting treatment outcome when used during standard TB chemotherapy."( Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro.
Anderson, R; Cholo, MC; Mashele, SA; Matjokotja, MT; Rasehlo, SSM; Steel, HC, 2022
)
2.45

Bioavailability

Administration of clofazimine with a high fat meal provides the greatest bioavailability, however, bioavailability is associated with high inter- and intra-subject variability. Clofazin has been anticipated for a candidate to treat tuberculosis, cryptosporidiosis, and coronavirus infection.

ExcerptReferenceRelevance
" Comparison of the bioavailability of clofazimine administered with or without food revealed a 60% higher mean area under the curve (AUC) value and a 30% higher mean maximum concentration (Cmax) value with food (N = 3)."( Pharmacokinetics of clofazimine in healthy volunteers.
Dieterle, W; Dubois, JP; Schaad-Lanyi, Z; Theobald, W; Vischer, W, 1987
)
0.87
" The calculated relative systemic bioavailability (Frel) of CLF from the coevaporate, relative to that from Lamprene, was three."( Comparative bioavailability of clofazimine coevaporate in the pig.
Abraham, I; Krishnan, TR, 1994
)
0.57
"We have studied the bioavailability of clofazimine following administration of a single dose of the drug in the biodegradable polymer polylactic-co-glycolic acid (PLGA)."( Bioavailability and chemotherapeutic activity of clofazimine against Mycobacterium avium complex infections in beige mice following a single implant of a biodegradable polymer.
Gangadharam, PR; Kailasam, S; Wise, DL, 1994
)
0.81
" This study was conducted to explore issues relating to bioavailability in the presence of food, orange juice, and antacid."( Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid.
Adam, RD; Auclair, B; Godo, PG; Krueger, TS; Nix, DE; Peloquin, CA, 2004
)
0.58
" The pharmacokinetics of clofazimine were assessed using individual- and population-based methods and relative bioavailability compared to fasting administration was determined."( Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid.
Adam, RD; Auclair, B; Godo, PG; Krueger, TS; Nix, DE; Peloquin, CA, 2004
)
0.88
"Administration of clofazimine with a high fat meal provides the greatest bioavailability, however, bioavailability is associated with high inter- and intra-subject variability."( Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid.
Adam, RD; Auclair, B; Godo, PG; Krueger, TS; Nix, DE; Peloquin, CA, 2004
)
0.91
" CFZ did not have a statistically significant effect on BDQ bioavailability (-9."( Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis.
Brill, MJE; Maartens, G; Pandie, M; Svensson, EM, 2018
)
0.73
"The low bioavailability and nonspecific distribution of dapsone and clofazimine, commonly applied in combination for the treatment of leprosy, can produce toxic effects."( Chromatographic method for the simultaneous quantification of dapsone and clofazimine in nanoformulations.
Barreiros, L; Chaves, LL; Fernandes, SR; Lima, SAC; Machado, S; Reis, S; Segundo, MA; Silva, EMP, 2018
)
0.95
"Interactions between hydrophobic drugs and endogenous gastrointestinal substances have the potential to manipulate drug concentration in the human gastrointestinal system, and thus likely play an important role in determining the rate of absorption for hydrophobic drugs."( Investigating the effects of amphipathic gastrointestinal compounds on the solution behaviour of salt and free base forms of clofazimine: An in vitro evaluation.
Bannigan, P; Hudson, SP; Kumar, A; Madden, C; Stokes, K, 2018
)
0.69
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Clofazimine, an anti-leprosy drug, has been anticipated for a candidate to treat tuberculosis, cryptosporidiosis, and coronavirus infection, but its low oral bioavailability is considered a reason for its limited activity."( Improvement and characterization of oral absorption behavior of clofazimine by SNEDDS: Quantitative evaluation of extensive lymphatic transport.
Higaki, K; Ishimaru, T; Kakuno, T; Kawatsu, S; Kondo, K; Maruyama, M; Takemoto, Y; Yamanouchi, K, 2023
)
2.59
" However, clinical implications may be restricted owing to poor solubility and low bioavailability rendering a suboptimal drug concentration in the target organ."( Clofazimine nanoclusters show high efficacy in experimental TB with amelioration in paradoxical lung inflammation.
Jadhav, K; Jhilta, A; Ray, E; Sharma, N; Shukla, R; Singh, AK; Singh, R; Verma, RK, 2023
)
2.35

Dosage Studied

The antileprosy drug clofazimine has shown potential for shortening tuberculosis treatment. The current dosing of the drug is not evidence based, and the optimal dosing is unknown.

ExcerptRelevanceReference
" The initial dosage of either of the drugs was 300 mg daily administered in divided doses of 100 mg three times a day."( Treatment of steroid dependant cases of recurrent lepra reaction with a combination of thalidomide and clofazimine.
Girdhar, A; Ramu, G, 1979
)
0.47
" The dosage was 200 mg daily and was increased to 400 mg daily."( [Pyoderma gangrenosum: Clofazimine therapy].
Beurey, J; Chaulieu, Y; Delrous, JL; Weber, M, 1977
)
0.57
" After 24 weeks of treatment, the patients were randomly allocated to treatment either with 200 mg B663 daily 6 days per week (regimen 6) or with dapsone, beginning with a small dosage and increasing over a period of 8 weeks to 100 mg daily 6 days per week (regimen 7)."( Spaced clofazimine therapy of lepromatous leprosy.
, 1976
)
0.71
"84 patients of leprosy including 15 female patients were treated with Clofzimine on a predetermined dosage regimen."( Side effects of clofazimine therapy.
Iyer, GG; Ramu, G, 1976
)
0.6
"Forty-five previously untreated lepromatous leprosy patients were allocated randomly to three groups and treated, respectively, with Regimen A, standard dosage of clofazimine (CLO) in multidrug therapy (MDT) regimen; Regimen B, CLO 600 mg once every 4 weeks; and Regimen C, CLO 1200 mg once every 4 weeks."( Short-term trial of clofazimine in previously untreated lepromatous leprosy.
Husser, JA; Jamet, P; Ji, B; Traore, I, 1992
)
0.8
" A dose-response experiment was performed with clarithromycin at 50, 100, 200, or 300 mg/kg of body weight administered daily by gavage to mice infected with approximately 10(7) viable MAC."( Activity of clarithromycin against Mycobacterium avium complex infection in beige mice.
Cynamon, MH; DeStefano, MS; Klemens, SP, 1992
)
0.28
" He received clofazimine (Lamprene) at a dosage of 100 mg twice daily."( Polychromatic corneal and conjunctival crystals secondary to clofazimine therapy in a leper.
Font, RL; Matoba, A; Sobol, W, 1989
)
0.89
"Five patients suffering from dermatitis ulcerosa (a variant of pyoderma gangrenosum) were treated with clofazimine in a daily dosage of 200 mg orally."( Clofazimine in dermatitis ulcerosa (pyoderma gangrenosum). Open clinical trial.
Mensing, H, 1988
)
1.93
" In a multiple-dose experiment, three volunteers were repeatedly dosed with 50 mg per day together with food for 8 days."( Pharmacokinetics of clofazimine in healthy volunteers.
Dieterle, W; Dubois, JP; Schaad-Lanyi, Z; Theobald, W; Vischer, W, 1987
)
0.6
" ENL was also more frequent in regimens C and D and was not prevented by CLO in the dosage used."( Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions.
Coussens, L; Groenen, G; Janssens, L; Kayembe, T; Nollet, E; Pattyn, SR, 1986
)
0.27
" To control ENL, they required high dosage of clofazimine and steroids for prolonged periods."( Oral zinc in recurrent Erythema Nodosum Leprosum reaction.
Bumb, RA; Mangal, HN; Mathur, NK, 1983
)
0.52
" When high dosage of clofazimine treatment is carried on during a long period, and drug accumulates in the tissues and precipitates as a solid."( [Enteropathy due to clofazimine treatment. A case report with an ultrastructural study].
Boutboul, R; Charpin, C; De Micco, C; Devaux, J; Toga, M, 1982
)
0.91
" Four patients, all of whom had taken clofazimine in relatively high dosage for many months, usually for ENL, complained about pigmentation."( Clofazimine (Lamprene, B663) in the treatment of lepromatous leprosy in the United Kingdom. A 12 year review of 31 cases, 1966-1978.
Browne, SG; Harman, DJ; McDougall, AC; Waudby, H, 1981
)
1.98
" The findings emphasize that clofazamine should not be used in high dosage over prolonged periods of time, except under close clinical and laboratory supervision, and for conditions not amenable to other drugs."( Splenic infarction and tissue accumulation of crystals associated with the use of clofazimine (Lamprene; B663) in the treatment of pyoderma gangrenosum.
Chaplin, AJ; Hede, JE; Horsfall, WR; McDougall, AC, 1980
)
0.49
" Recurrences have been suppressed with a reduced maintenance dosage of this agent."( Granulomatous glossitis as an unusual manifestation of Melkersson-Rosenthal syndrome.
Boateng, BI; Hornstein, OP; Kiesewetter, FF; Mahler, VB, 1995
)
0.29
" Its optimal dosage appears to be 400 mg daily, and combination with dapsone and clofazimine does not enhance its activity."( Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy.
Grosset, JH; Ji, B; N'Deli, L; Perani, EG; Petinom, C, 1994
)
0.75
" Tolerance to the drugs was generally good, apart from three cases of hepatic disturbances and three cases of ototoxicity, which required a decrease in clarithromycin dosage after a short interruption of treatment."( Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections à Mycobactéries.
Igual, J; Roussel, G, 1998
)
0.58
" In many cases dose and intervals were based on WHO protocol, however smaller dosage was used in some cases."( [Chemotherapy of Hansen's disease in Japan--present status].
Goto, M; Kitajima, S; Miyagi, S; Takizawa, H, 1998
)
0.3
" The Data and Safety Monitoring Board recommended discontinuation of the clarithromycin dosage comparison and continuation of the rifabutin vs."( A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Resear
Chesnut, J; Child, CC; Clotfelter, J; Cohn, DL; El-Sadr, W; Fisher, EJ; Franchino, B; Gibert, CL; Hafner, R; Heifets, L; Hodges, JS; Horsburgh, CR; Korvick, J; Munroe, D; Peng, GT; Ropka, M, 1999
)
0.3
" CS is significantly removed by hemodialysis and should be dosed after hemodialysis."( The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine.
Childs, JM; Fish, DN; Malone, RS; Peloquin, CA; Spiegel, DM, 1999
)
0.53
" Under clofazimine (Lampren), at an initial dosage of 3 x 100 mg daily by mouth, gradually reduced over 4 months, the cutaneous lesions healed completely and lastingly."( [Disseminated small-node cutaneous sarcoidosis].
Djawari, D; Schwarzenbach, R, 2000
)
0.76
" It was concluded that solid-dispersion formulations of Clofazimine can be used to design a solid dosage form of the drug, which would have significant advantages over the currently marketed soft gelatin capsule dosage form."( Evaluation of solid dispersions of Clofazimine.
Narang, AS; Srivastava, AK, 2002
)
0.84
" The results of the study therefore reveal that patients undergoing therapy had significantly greater DNA damage than untreated patients, indicating bacterial infection and drug therapy as the causal factors, since lepromatous-type disease is the more severe form with the patients having lower resistance to Mycobacterium leprae and requiring heavier and prolonged dosage of antibiotics."( DNA damage studies in untreated and treated leprosy patients.
Gandhi, G; Singh, B, 2004
)
0.32
" Prednisolone in standard dosage schedule as recommended by WHO is now being widely used in control programmes."( Reactions and their management.
Ganapati, R; Pai, VV, 2004
)
0.32
" An autopsy study was done on a 45 year old female of lepromatous leprosy (LL) on MDT and long term high dosage of clofazimine."( Tissue concentration, systemic distribution and toxicity of clofazimine--an autopsy study.
Deore, SS; Jadhav, MV; Joghi, NG; Joshi, NG; Patil, PG; Sathe, AG, 2004
)
0.78
" Ramp-up dosing was used."( Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars.
Bilkey, S; Borody, TJ; Leis, S; Pang, G; Tye, S; Wettstein, AR, 2007
)
0.34
" Our results demonstrated that the dosage of dapsone in leprosy treatment does not promote a significant methemoglobinemia."( Methemoglobinemia and dapsone levels in patients with leprosy.
Martins, Ade N; Riveira, JG; Salgado, CG; Silva, JP; Vieira, JL,
)
0.13
" Eleven of these more water-soluble riminophenazine analogs possess shorter half-lives than clofazimine when dosed orally to mice, suggesting that they may accumulate less."( Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation.
Fu, L; Huang, H; Jin, H; Li, P; Lu, Y; Ma, Z; Upton, AM; Wang, B; Xu, J; Yin, D; Zhao, W; Zheng, M; Zhu, H, 2011
)
2.03
"The antileprosy drug clofazimine has shown potential for shortening tuberculosis treatment; however, the current dosing of the drug is not evidence based, and the optimal dosing is unknown."( Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis.
Adamson, J; Almeida, DV; Ammerman, NC; Bester, LA; Dorasamy, A; Grosset, JH; Mgaga, Z; Moodley, C; Moodley, S; Ngcobo, B; Singh, S; Swanson, RV; Tapley, A, 2015
)
1
" Daily and weekly dosing schedules were evaluated against Pgp-expressing human colon adenocarcinoma (HCT-15) xenografts implanted subcutaneously in athymic mice."( Anticancer efficacy and toxicokinetics of a novel paclitaxel-clofazimine nanoparticulate co-formulation.
Cromarty, D; Koot, D, 2015
)
0.66
" In a mouse model of acute cryptosporidiosis, a once daily dosage regimen for three consecutive days or a single high dose resulted in reduction of oocyst shedding below the limit detectable by flow cytometry."( A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.
Beasley, FC; Chatterjee, AK; Huston, CD; Jumani, RS; Love, MS; McNamara, CW; Schultz, PG; Wright, TM, 2017
)
0.71
" However, clofazimine causes dose- and duration-dependent skin discoloration in patients, and the optimal clofazimine dosing strategy in the context of the first-line regimen is unknown."( Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.
Almeida, DV; Ammerman, NC; Bautista, EM; Bester, LA; Betoudji, F; Chaisson, RE; Chang, YS; Grosset, JH; Guo, H; Li, SY; Moodley, C; Ngcobo, B; Nuermberger, E; Omansen, TF; Pillay, L; Saini, V; Singh, SD; Swanson, RV; Tapley, A; Tasneen, R; Tyagi, S, 2018
)
1.29
" Additional preclinical studies are required to identify the minimal dose and dosage of CFZ for babesiosis."( Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts.
Gantuya, S; Guswanto, A; Igarashi, I; Krause, PJ; Sivakumar, T; Tayebwa, DS; Tuvshintulga, B; Vannier, E; Yokoyama, N, 2020
)
2
"To determine clofazimine exposure, evaluate covariate effects on variability, and simulate exposures for different dosing strategies in South African TB patients."( Clofazimine pharmacokinetics in patients with TB: dosing implications.
Abdelwahab, MT; Brust, JCM; Dawson, R; Denti, P; Diacon, A; Everitt, D; Gandhi, NR; Maartens, G; Meintjes, G; Svensson, EM; Wasserman, S; Wiesner, L, 2020
)
2.37
" Disposition was strongly influenced by body fat content, with potential dosing implications for women with TB."( Clofazimine pharmacokinetics in patients with TB: dosing implications.
Abdelwahab, MT; Brust, JCM; Dawson, R; Denti, P; Diacon, A; Everitt, D; Gandhi, NR; Maartens, G; Meintjes, G; Svensson, EM; Wasserman, S; Wiesner, L, 2020
)
2
"We found a strong association of weight with bedaquiline and clofazimine exposure parameters, suggesting the need for weight-based dosing for those agents."( Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis.
Al-Shaer, MH; Alghamdi, WA; Barbakadze, K; Kempker, RR; Kipiani, M; Mikiashvili, L; Peloquin, CA, 2021
)
1.12
" Weight-based dosing in patients <50 kg and ≥50 kg must be considered to achieve optimal treatment outcomes and reduce adverse events."( Dose-related treatment outcomes in South African patients prescribed clofazimine for drug-resistant tuberculosis.
Misra, N; Naidoo, P; Padayatchi, N, 2020
)
0.79
" The primary CFZ dosage was 50 mg/day."( Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infection.
Fujiwara, K; Furuuchi, K; Hanada, K; Hiramatsu, M; Kurashima, A; Morimoto, K; Ohta, K; Shiraishi, Y; Uesugi, F; Watanabe, F; Yoshiyama, T, 2022
)
0.99
" Increased lung and spleen accumulation of the drug after pulmonary administration was noted in infected mice compared to naive mice, while the opposite trend was noted in the oral dosing groups."( Respirable Clofazimine Particles Produced by Air Jet Milling Technique Are Efficacious in Treatment of BALB/c Mice with Chronic Mycobacterium tuberculosis Infection.
Brunaugh, AD; Gonzalez-Juarrero, M; Koleng, JJ; Munoz Gutierrez, J; Pearce, C; Smyth, HDC; Walz, A; Warnken, Z, 2022
)
1.11
" As an opportunistic pathogen with increasing antibiotics resistance, prolonged systemic dosing with multiple antibiotics remains the primary treatment paradigm."( Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection.
Doyle-Eisele, M; Grant, M; Hittinger, M; Hofmann, T; Kuehl, P; Kunkel, M; Reed, M; Rotermund, K; Ufer, S, 2023
)
2.35
" The aim of this research was to develop stable extemporaneous liquid formulations of CFZ that can be stored at room temperature for several weeks to enable practical dosing in the field."( Extemporaneously compounded liquid formulations of clofazimine.
Fourie, CL; Garcia-Prats, AJ; Hesseling, AC; Hoddinott, G; Jew, RK; Nahata, MC; Pande, PG; Scarim, A; Scarim, J; Schaaf, HS; Taneja, R, 2023
)
1.16
" However, the lack of a dividable oral dosage form has limited the use of the drug in pediatric populations, who may require lowering of the dose to reduce the likelihood of adverse drug events."( Development of low-cost, weight-adjustable clofazimine mini-tablets for treatment of tuberculosis in pediatrics.
Brunaugh, A; Koleng, JJ; Martins, PP; Parekh, J; Smyth, HDC; Trementozzi, A; Warnken, Z, 2023
)
1.17
" Few serious adverse events occurred for ALIS users; however, reduction of dosing to three times weekly was common (52%)."( Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease.
Brown-Elliott, BA; Brunton, AE; Fuss, C; Griffith, DE; Philley, JV; Siegel, SAR; Strnad, L; Sullivan, PE; Wallace, RJ; Winthrop, KL, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
leprostatic drugA substance that suppresses Mycobacterium leprae, ameliorates the clinical manifestations of leprosy, and/or reduces the incidence and severity of leprous reactions.
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
dyenull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
phenazinesAny organonitrogen heterocyclic compound based on a phenazine skeleton and derivatives.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (46)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency7.07950.631035.7641100.0000AID504339
phosphopantetheinyl transferaseBacillus subtilisPotency31.62280.141337.9142100.0000AID1490
USP1 protein, partialHomo sapiens (human)Potency15.84890.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency13.06380.000811.382244.6684AID686978; AID686979
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency5.22760.00137.762544.6684AID914; AID915
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.69330.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency9.65450.000214.376460.0339AID720691; AID720692
estrogen nuclear receptor alphaHomo sapiens (human)Potency13.52230.000229.305416,493.5996AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency1.69330.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency1.34500.00108.379861.1304AID1645840
67.9K proteinVaccinia virusPotency10.00000.00018.4406100.0000AID720580
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency2.51190.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency2.51190.00207.533739.8107AID891
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency28.18380.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency4.46680.006026.168889.1251AID540317
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency7.07950.01789.637444.6684AID588834
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency53.13800.794321.275750.1187AID624246; AID651804
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency5.82990.000323.4451159.6830AID743065; AID743067
importin subunit beta-1 isoform 1Homo sapiens (human)Potency52.30545.804836.130665.1308AID540253; AID540263
mitogen-activated protein kinase 1Homo sapiens (human)Potency3.16230.039816.784239.8107AID995
eyes absent homolog 2 isoform aHomo sapiens (human)Potency1.90151.199814.641950.1187AID720540
snurportin-1Homo sapiens (human)Potency52.30545.804836.130665.1308AID540253; AID540263
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency4.61095.804816.996225.9290AID540253
gemininHomo sapiens (human)Potency1.25890.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency6.91110.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency11.22020.891312.067628.1838AID1487
Interferon betaHomo sapiens (human)Potency1.69330.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency1.69330.01238.964839.8107AID1645842
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
C-terminal-binding protein 1Homo sapiens (human)Potency3.38140.30149.321019.0148AID720541
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency1.69330.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency1.69330.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)21.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)44.50000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)16.85000.11007.190310.0000AID1443980; AID1443989; AID1473738; AID681139
ATP-dependent translocase ABCB1Homo sapiens (human)IC50 (µMol)0.90000.00022.318510.0000AID681126; AID681127; AID681131
CruzipainTrypanosoma cruziIC50 (µMol)23.00000.00022.04508.0000AID1198504; AID1198505; AID484274; AID484275
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)10.40002.41006.343310.0000AID1473739
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)3.20000.00401.966610.0000AID1873198
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
mitogen-activated protein kinase kinase kinase kinase 2 isoform 1Homo sapiens (human)EC50 (µMol)15.15500.67008.534426.3600AID1895; AID1897
streptokinase A precursorStreptococcus pyogenes M1 GASEC50 (µMol)1.76200.06008.9128130.5170AID1902; AID1914
mitogen-activated protein kinase kinase kinase 3 isoform 1Homo sapiens (human)EC50 (µMol)30.00002.68006.670011.8600AID1896
Estrogen receptorRattus norvegicus (Norway rat)EC50 (µMol)2.28100.006022.3670130.5170AID1914
Spike glycoproteinSevere acute respiratory syndrome coronavirus 2Kd3.82000.03791.92893.8200AID1904975
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)EC50 (µMol)30.00000.00543.251020.9400AID1897
Estrogen receptor betaRattus norvegicus (Norway rat)EC50 (µMol)2.28100.006022.3670130.5170AID1914
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (116)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIC-terminal-binding protein 1Homo sapiens (human)
protein phosphorylationC-terminal-binding protein 1Homo sapiens (human)
negative regulation of cell population proliferationC-terminal-binding protein 1Homo sapiens (human)
viral genome replicationC-terminal-binding protein 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionC-terminal-binding protein 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionC-terminal-binding protein 1Homo sapiens (human)
synaptic vesicle endocytosisC-terminal-binding protein 1Homo sapiens (human)
white fat cell differentiationC-terminal-binding protein 1Homo sapiens (human)
regulation of cell cycleC-terminal-binding protein 1Homo sapiens (human)
synaptic vesicle clusteringC-terminal-binding protein 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIC-terminal-binding protein 1Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (62)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
transcription corepressor bindingC-terminal-binding protein 1Homo sapiens (human)
chromatin bindingC-terminal-binding protein 1Homo sapiens (human)
transcription corepressor activityC-terminal-binding protein 1Homo sapiens (human)
protein bindingC-terminal-binding protein 1Homo sapiens (human)
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptorC-terminal-binding protein 1Homo sapiens (human)
protein domain specific bindingC-terminal-binding protein 1Homo sapiens (human)
identical protein bindingC-terminal-binding protein 1Homo sapiens (human)
NAD bindingC-terminal-binding protein 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingC-terminal-binding protein 1Homo sapiens (human)
DNA-binding transcription factor bindingC-terminal-binding protein 1Homo sapiens (human)
transcription coactivator activityC-terminal-binding protein 1Homo sapiens (human)
transcription coregulator bindingC-terminal-binding protein 1Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (40)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneSpike glycoproteinSevere acute respiratory syndrome coronavirus 2
virion membraneSpike glycoproteinSevere acute respiratory syndrome coronavirus 2
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
nucleusC-terminal-binding protein 1Homo sapiens (human)
nucleoplasmC-terminal-binding protein 1Homo sapiens (human)
presynaptic active zone cytoplasmic componentC-terminal-binding protein 1Homo sapiens (human)
glutamatergic synapseC-terminal-binding protein 1Homo sapiens (human)
GABA-ergic synapseC-terminal-binding protein 1Homo sapiens (human)
transcription repressor complexC-terminal-binding protein 1Homo sapiens (human)
nucleusC-terminal-binding protein 1Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (262)

Assay IDTitleYearJournalArticle
AID1473893Ratio of drug concentration at steady state in human at 100 to 300 mg, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID564977Antimicrobial activity against Mycobacterium bovis BCG KOP55 harboring inactivated p55 gene by twofold dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1224527Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 131 after 7 days by micromethod2014European journal of medicinal chemistry, Jul-23, Volume: 821-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria.
AID1435651Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 9449/2007 after 14 days by micromethod2017European journal of medicinal chemistry, Jan-27, Volume: 126S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents.
AID1198509Trypanocidal activity against GFP expressing Trypanosoma cruzi Y epimastigotes assessed as inhibition of parasite proliferation at 1 uM to 20 uM and measured after 2 to 8 days by hemocytometry based cell counting method2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID1176093Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 assessed as inhibition of parasite growth after 72 hrs by parasite lactate dehydrogenase assay2015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Clofazimine analogs with antileishmanial and antiplasmodial activity.
AID564995Effect on intracellular redox potential in Mycobacterium bovis BCG KOP55 harboring pPAZ23 carrying p27-p55 operon assessed as accumulation of formazan at 5 mg/liter after 1 hr by MTT assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1518990Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as reduction in parasite burden in cardiac muscle at 30 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post i2019European journal of medicinal chemistry, 12-15, Volume: 184Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID285159Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID1224523Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 1 after 7 days by micromethod2014European journal of medicinal chemistry, Jul-23, Volume: 821-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria.
AID1904972Antiviral activity against S-protein based pseudotyped SARS-CoV-2 infected in Huh7 cells measured after 24 hrs by bright-Glo luciferase assay2022European journal of medicinal chemistry, Apr-15, Volume: 234Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism.
AID1055953Antimycobacterial activity against Mycobacterium smegmatis ATCC 700084 under normoxic condition after 72 hrs by MABA assay2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Hytramycins V and I, anti-Mycobacterium tuberculosis hexapeptides from a Streptomyces hygroscopicus strain.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID484276Colloidal aggregation in fed state simulated intestinal fluid by dynamic light scattering assay in presence of 1% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1767527Inhibition of Wnt signalling in human BT-20 cells transfected with Renilla luciferase preincubated for 1 hr followed by wnt3a addition by TopFlash luciferase reporter assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Optimization of the clofazimine structure leads to a highly water-soluble C3-aminopyridinyl riminophenazine endowed with improved anti-Wnt and anti-cancer activity in vitro and in vivo.
AID1435649Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 4 after 14 days by micromethod2017European journal of medicinal chemistry, Jan-27, Volume: 126S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents.
AID1176091Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 assessed as inhibition of parasite growth after 72 hrs by parasite lactate dehydrogenase assay2015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Clofazimine analogs with antileishmanial and antiplasmodial activity.
AID484383Colloidal aggregation in fed state simulated intestinal fluid assessed as colloid radius at 10 uM by dynamic light scattering assay in presence of 1% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1198529Plasma concentration in leprosy patient at 600 mg/kg, po dosed daily2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID1296385Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis 8666/2010 after 14 days by microdilution method2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.
AID564972Antimicrobial activity against Mycobacterium bovis BCG by twofold dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID707866Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.
AID1198534Trypanocidal activity against GFP expressing Trypanosoma cruzi Y C57BL/6J mouse acute model of trypanosomal infection assessed as reduction in cardiac amastigote nests counts at 20 mg/kg/day, ip measured at 10,14 and 20 days post infection by HE staining 2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID1198515Trypanocidal activity against GFP expressing Trypanosoma cruzi Y epimastigotes in rat H9C2 cell monolayers for 12 hrs infected with 30 mins compound pre-treated parasite obtained from infected African green monkey Vero cells assessed as reduction in paras2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID1198523Cytotoxicity against rat H9c2 cells assessed as effect on metabolic activity at 5 uM by alamar blue assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID1883689Bactericidal activity against Mycobacterium tuberculosis H37Rv in chronic Mtb infection BALB/c mouse model assessed as log10 CFU kill at 20 mg/kg, po qd via gavage measured after 4 weeks2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Tuberculosis Drug Discovery: Challenges and New Horizons.
AID1904979Binding affinity to SARS-CoV-2 spike protein at 0.16 to 1.25 uM by SPR analysis2022European journal of medicinal chemistry, Apr-15, Volume: 234Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID144311100% inhibition of growth of clofazimine resistant Mycobacterium smegmatis 607 strain in vitro1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Clofazimine analogues active against a clofazimine-resistant organism.
AID1176092Selectivity index, ratio of IC50 for HMEC1 to IC50 for chloroquine-sensitive Plasmodium falciparum D102015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Clofazimine analogs with antileishmanial and antiplasmodial activity.
AID707859AUC (0 to 24 hrs) in BALB/c mouse at 20 mg/kg, po2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.
AID1174925Antitubercular activity against Mycobacterium tuberculosis isolate 756/10 after 7 days by REMA resazurin microtiter assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.
AID1174932Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to MIC for Mycobacterium tuberculosis H37Rv2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.
AID1286509Antibacterial activity against Escherichia coli ATCC 25922 after 20 to 24 hrs2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Robenidine Analogues as Gram-Positive Antibacterial Agents.
AID1782219Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 incubated for 7 days by broth dilution method2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Functionalized Dioxonaphthoimidazoliums: A Redox Cycling Chemotype with Potent Bactericidal Activities against
AID1174927Antitubercular activity against Mycobacterium tuberculosis isolate 917/10 after 7 days by REMA resazurin microtiter assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1577331Antimycobacterial activity against XDR Mycobacterium tuberculosis Praha 131 after 14 days2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1224519Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 9449/2007 after 7 days by micromethod2014European journal of medicinal chemistry, Jul-23, Volume: 821-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria.
AID1198510Trypanocidal activity against GFP expressing Trypanosoma cruzi Y epimastigotes assessed as inhibition of parasite proliferation at 1 uM to 20 uM and measured after 4 days by hemocytometry based cell counting method2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID1577339Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis 8666/2010 after 14 days2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1519011Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as adipocytes replacement in skeletal muscle by measuring number of adipocyte at 30 mg/kg/day, po administered via gavage for 30 consecutive days 2019European journal of medicinal chemistry, 12-15, Volume: 184Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID564996Effect on intracellular redox potential in wild-type Mycobacterium bovis BCG assessed as accumulation of formazan at 5 mg/liter after 1 hr by MTT assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1463959Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate 9449/2007 incubated for 14 days by micromethod2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents.
AID707864Selectivity index, ratio of IC50 for african green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv ATCC 272942012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.
AID1518981Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as effect on QT interval at 30 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection and measured at 2019European journal of medicinal chemistry, 12-15, Volume: 184Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1176085Antileishmanial activity against Leishmania infantum MHOM/TN/80/IPT1 promastigotes assessed as inhibition of parasite growth after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Clofazimine analogs with antileishmanial and antiplasmodial activity.
AID1162168Antitubercular activity against Mycobacterium tuberculosis assessed as growth inhibition2014European journal of medicinal chemistry, Oct-30, Volume: 86SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1174923Antitubercular activity against Mycobacterium tuberculosis isolate 29/10 after 7 days by REMA resazurin microtiter assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.
AID1174917Cytotoxicity against african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT method2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.
AID765268T>MIC in Mycobacterium tuberculosis infected mouse2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1518983Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as effect on PR interval at 30 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection and measured at 2019European journal of medicinal chemistry, 12-15, Volume: 184Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1162166Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition2014European journal of medicinal chemistry, Oct-30, Volume: 86SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
AID1176088Selectivity index, ratio of IC50 for HMEC1 to IC50 for Leishmania tropica MHOM/IT/2012/ISS31302015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Clofazimine analogs with antileishmanial and antiplasmodial activity.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1174930Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 96 hrs by MTT method2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1767529Selectivity index, ratio of IC50 for cytotoxicity against human human BT-20 cells incubated for 3 to 4 days by MTT assay to IC50 for Wnt signalling in human BT-20 cells transfected with Renilla luciferase preincubated for 1 hr followed by wnt3a addition b2021European journal of medicinal chemistry, Oct-15, Volume: 222Optimization of the clofazimine structure leads to a highly water-soluble C3-aminopyridinyl riminophenazine endowed with improved anti-Wnt and anti-cancer activity in vitro and in vivo.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1767528Cytotoxicity against human BT-20 cells incubated for 3 to 4 days by MTT assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Optimization of the clofazimine structure leads to a highly water-soluble C3-aminopyridinyl riminophenazine endowed with improved anti-Wnt and anti-cancer activity in vitro and in vivo.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID250135Inhibition of compound against MES-SA/DX5 cell line was determined using P-glycoprotein assay2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR.
AID707858Acute toxicity in mouse2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.
AID1198526Plasma concentration in leprosy patient at 100 mg/kg, po dosed daily2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID1198506Inhibition of Trypanosoma cruzi cruzaine at 100 uM using mMBz-Pro-Phe-Arg-pNA substrate incubated for for 5 mins by UV-vis spectrophotometry2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID1904970Selectivity index, ratio of CC50 for cytotoxicity against golden hamster BSR cells to EC50 for antirabies activity against Rabies virus infected in golden hamster BSR cells2022European journal of medicinal chemistry, Apr-15, Volume: 234Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism.
AID1198508Trypanocidal activity against GFP expressing Trypanosoma cruzi Y epimastigotes in rat H9C2 cell monolayers for 24 hrs infected with 30 mins compound pre-treated parasite obtained from infected African green monkey Vero cells assessed as reduction in paras2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID145273Minimum inhibitory concentration against (MDR-TB) Mycobacterium tuberculosis using microplate alamar blue assay2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Anilinopyrimidines as novel antituberculosis agents.
AID765272Cmax/MIC in Mycobacterium tuberculosis infected mouse2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
AID1519003Cytotoxicity against African green monkey Vero cells at 0.5 to 20 uM after 72 hrs by propidium iodide staining based flow cytometric analysis2019European journal of medicinal chemistry, 12-15, Volume: 184Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1286517Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 20 to 24 hrs in presence of polymyxin B nonapeptide2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Robenidine Analogues as Gram-Positive Antibacterial Agents.
AID144314100% inhibition of growth of rifampicin resistant Mycobacterium smegmatis 607 strain in vitro1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Clofazimine analogues active against a clofazimine-resistant organism.
AID564969Upregulation of p55 gene expression Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID765273fCmax/MIC in Mycobacterium tuberculosis infected mouse2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1198511Trypanocidal activity against GFP expressing Trypanosoma cruzi Y epimastigotes assessed as inhibition of parasite proliferation at 20 uM measured after few hrs by hemocytometry based cell counting method2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID1463956Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate Praha 1 incubated for 14 days by micromethod2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1653417Inhibition of PGL1 synthesis in Mycobacterium leprae infected Swiss Webster mouse macrophages assessed as decrease in [U-14C]PA incorporation at 2 uM preincubated for 4 days post infection followed by [U-14C]PA addition and measured after 7 days by liquid2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID1198516Trypanocidal activity against GFP expressing Trypanosoma cruzi Y epimastigotes in rat H9C2 cell monolayers for 12 hrs infected with 30 mins compound pre-treated parasite obtained from infected African green monkey Vero cells assessed as reduction in cell 2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID484275Inhibition of Trypanosoma cruzi cruzaine preincubated for 5 mins before substrate addition by fluorescence assay in presence of 0.01% Triton X-1002010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1443989Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell plasma membrane vesicles assessed as reduction in ATP-dependent [3H]-taurocholate uptake in to vesicles preincubated for 10 mins followed by ATP addition measured after 10 to 2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1473894Ratio of drug concentration at steady state in human at 100 to 300 mg, po QD after 24 hrs to IC50 for human MRP2 overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1577329Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis Praha 4 after 14 days2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.
AID1463957Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate Praha 4 incubated for 14 days by micromethod2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1518986Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as change in QRS morphology at 30 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection and measured 2019European journal of medicinal chemistry, 12-15, Volume: 184Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID681126TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1435652Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 234/2005 after 14 days by micromethod2017European journal of medicinal chemistry, Jan-27, Volume: 126S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID765270AUC/MIC in Mycobacterium tuberculosis infected mouse2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
AID564970Downregulation of p27 gene expression Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1176086Selectivity index, ratio of IC50 for HMEC1 to IC50 for Leishmania infantum MHOM/TN/80/IPT12015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Clofazimine analogs with antileishmanial and antiplasmodial activity.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1162172Antitubercular activity against drug-resistant Mycobacterium tuberculosis clinical isolates assessed as growth inhibition2014European journal of medicinal chemistry, Oct-30, Volume: 86SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
AID1198513Trypanocidal activity against GFP expressing Trypanosoma cruzi Y epimastigotes assessed as effect on parasite morphology at 1 uM to 20 uM measured after 1 to 3 days by hemocytometry based cell counting method2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID1904973Selectivity index, ratio of CC50 for cytotoxicity against human Huh7 cells to EC50 for antiviral activity against S-protein based pseudotyped SARS-CoV-2 infected in Huh7 cells2022European journal of medicinal chemistry, Apr-15, Volume: 234Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism.
AID707857Antitubercular activity against multi-drug resistant Mycobacterium tuberculosis isolate 040 infected in BALB/c mouse assessed as reduction in lung bacterial load at 20 mg/kg, po qd administered 5 days per week during acute phase of infection measured afte2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.
AID1224521Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 8666/2010 after 7 days by micromethod2014European journal of medicinal chemistry, Jul-23, Volume: 821-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria.
AID1174926Antitubercular activity against Mycobacterium tuberculosis isolate 778/10 after 7 days by REMA resazurin microtiter assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.
AID285161Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID1435654Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 8666/2010 after 14 days by micromethod2017European journal of medicinal chemistry, Jan-27, Volume: 126S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents.
AID1198505Inhibition of Trypanosoma cruzi cruzaine in absence of 0.01% Triton2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID1659807Antimycobacterial activity against multi drug-resistant Mycobacterium tuberculosis2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Molecule Property Analyses of Active Compounds for
AID1873198Inhibition of ABCG2 (unknown origin) expressed in human HEK293 cells membrane vesicles assessed inhibition of BCRP- mediated transport of 3[H]-E1S for 1 mins using [3H]-estrone sulfate as substrate by rapid filtration technique2022European journal of medicinal chemistry, Jul-05, Volume: 237Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID1129946Antimicrobial activity against Mycobacterium avium complex by BACTEC radiometric assay2014Journal of natural products, Apr-25, Volume: 77, Issue:4
Genomics-guided discovery of endophenazines from Kitasatospora sp. HKI 714.
AID1473896Ratio of drug concentration at steady state in human at 100 to 300 mg, po QD after 24 hrs to IC50 for human MRP4 overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1518987Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as change in QRS morphology at 30 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection and measured 2019European journal of medicinal chemistry, 12-15, Volume: 184Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1518977Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as effect on heart rate duration at 30 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection and meas2019European journal of medicinal chemistry, 12-15, Volume: 184Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1904977Binding affinity to rabies recombinant GST-His-tagged G-glycoprotein protein (20 to 459 AA residues) expressed in Escherichia coli BL21 (DE3) cells assessed as Kd treated for 60 secs followed dissociation time of 120 secs by SPR analysis2022European journal of medicinal chemistry, Apr-15, Volume: 234Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism.
AID681131TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID1174933Lipophilicity, logD of the compound at pH 7.42014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.
AID564968Upregulation of p27 gene expression in Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1198504Inhibition of Trypanosoma cruzi cruzaine in presence of 0.01% Triton2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID285162Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID1176096Cytotoxicity against HMEC1 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Clofazimine analogs with antileishmanial and antiplasmodial activity.
AID1519015Toxicity in C3H/HeNk mouse infected with Trypanosoma cruzi K98 bloodstream form assessed as body weight gain at 30 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection measured up to 120 days post infection in2019European journal of medicinal chemistry, 12-15, Volume: 184Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1473892Drug concentration at steady state in human at 100 to 300 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1519007Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as reduction in cardiac tissue inflammation at 30 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infecti2019European journal of medicinal chemistry, 12-15, Volume: 184Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1174918Half life in human2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.
AID564987Antimicrobial activity against Mycobacterium bovis BCG harboring pPAZ23 carrying p27-p55 operon by twofold dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID484274Inhibition of Trypanosoma cruzi cruzaine preincubated for 5 mins before substrate addition by fluorescence assay in absence of Triton X-1002010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID707867Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by microplate Alamar blue assay2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1518979Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as effect on heart rate at 30 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection and measured at 12019European journal of medicinal chemistry, 12-15, Volume: 184Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1129947Antimicrobial activity against Mycobacterium tuberculosis by BACTEC radiometric assay2014Journal of natural products, Apr-25, Volume: 77, Issue:4
Genomics-guided discovery of endophenazines from Kitasatospora sp. HKI 714.
AID1577333Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis 9449/2007 after 21 days2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.
AID1463962Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate 8666/2010 incubated for 14 days by micromethod2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents.
AID1678478Inhibition of recombinant His6-tagged SARS-CoV-2 main protease assessed as residual enzyme activity at 100 uM using Dabcyl-KTSAVLQ-SGFRKM-E(Edans-NH2) as substrate preincubated for 15 mins followed by substrate addition by FRET based assay relative to con2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
AID1296384Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis 9449/2007 after 14 days by microdilution method2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.
AID564994Decrease in intracellular redox potential in Mycobacterium bovis BCG KOP55 harboring inactivated p55 gene assessed as decreased accumulation of formazan at 5 mg/liter after 1 hr by MTT assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1577327Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis Praha 1 after 14 days2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.
AID1286516Antibacterial activity against Escherichia coli ATCC 25922 after 20 to 24 hrs in presence of polymyxin B nonapeptide2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Robenidine Analogues as Gram-Positive Antibacterial Agents.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID484391Colloidal aggregation in fed state simulated intestinal fluid at 600 uM by dynamic light scattering-based beads autocorrelation assay in presence of 6% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1198514Trypanocidal activity against GFP expressing Trypanosoma cruzi Y epimastigotes assessed as effect on parasite motility at 1 uM to 20 uM measured after 1 to 3 days by hemocytometry based cell counting method2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID564982Antimicrobial activity against Mycobacterium bovis BCG KOP55 harboring pPAZ23 carrying p27-p55 operon by twofold dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1518991Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as reduction in parasite burden in skeletal muscle at 30 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post 2019European journal of medicinal chemistry, 12-15, Volume: 184Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1653419Inhibition of PGL1 synthesis in Mycobacterium leprae infected Swiss Webster mouse macrophages assessed as decrease in [U-14C]PA incorporation at 0.2 uM preincubated for 4 days post infection followed by [U-14C]PA addition and measured after 7 days by liqu2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1286510Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 20 to 24 hrs2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Robenidine Analogues as Gram-Positive Antibacterial Agents.
AID1473891Cmax in human at 100 to 300 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1904969Antirabies activity against rabies CVS infected in golden hamster BSR cells preincubated for 1 hr followed by mixing of cells measured after 24 hrs by inverted fluorescence microscope analysis2022European journal of medicinal chemistry, Apr-15, Volume: 234Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism.
AID484299Colloidal aggregation in fed state simulated intestinal fluid assessed as colloid radius at 600 uM by dynamic light scattering assay in presence of 1% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID707862Cmax in BALB/c mouse at 20 mg/kg, po2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.
AID1174931Selectivity index, ratio of CC50 for human MT4 cells to MIC for Mycobacterium tuberculosis H37Rv2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.
AID1296387Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis Praha 4 after 14 days by microdilution method2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.
AID1176087Antileishmanial activity against Leishmania tropica MHOM/IT/2012/ISS3130 promastigotes assessed as inhibition of parasite growth after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Clofazimine analogs with antileishmanial and antiplasmodial activity.
AID681139TP_TRANSPORTER: increase in dihydrofluorescein intracellular accumulation (dihydrofluorescein: 1 uM) in SK-E2 cells (expressing BSEP)2003Pharmaceutical research, Apr, Volume: 20, Issue:4
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1296383Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis 234/2005 after 14 days by microdilution method2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.
AID1473895Ratio of drug concentration at steady state in human at 100 to 300 mg, po QD after 24 hrs to IC50 for human MRP3 overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID765271fAUC/MIC in Mycobacterium tuberculosis infected mouse2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
AID1577337Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis 7357/1998 after 21 days2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.
AID1174929Selectivity index, ratio of CC50 for human HMEC1 cells to MIC for Mycobacterium tuberculosis H37Rv2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1519005Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as reduction in parasite burden in blood at 30 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection 2019European journal of medicinal chemistry, 12-15, Volume: 184Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID144313Concentration for 100% inhibition of growth of dapsone sensitive Mycobacterium smegmatis 607 strain in vitro1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Clofazimine analogues active against a clofazimine-resistant organism.
AID1463961Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate 7357/1998 incubated for 14 days by micromethod2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents.
AID1174920Antitubercular activity against Mycobacterium tuberculosis H37Rv after 7 days by REMA resazurin microtiter assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.
AID1198528Plasma concentration in leprosy patient at 400 mg/kg, po dosed daily2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID1174928Cytotoxicity against human HMEC1 cells assessed as reduction in cell viability after 72 hrs by MTT method2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1162174Antitubercular activity against Mycobacterium tuberculosis infected in mouse assessed as reduction in colony formation at 20 mg/kg for 20 days2014European journal of medicinal chemistry, Oct-30, Volume: 86SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
AID1463960Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate 234/2005 incubated for 14 days by micromethod2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents.
AID1174924Antitubercular activity against Mycobacterium tuberculosis isolate 439/11 after 7 days by REMA resazurin microtiter assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID564971Downregulation of p55 gene expression Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID484298Colloidal aggregation in fed state simulated intestinal fluid by dynamic light scattering assay in presence of 6% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1198536Toxicity in orally dosed mouse2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1176094Resistance index, ratio of IC50 for chloroquine-resistant Plasmodium falciparum W2 to IC50 for chloroquine-sensitive Plasmodium falciparum D102015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Clofazimine analogs with antileishmanial and antiplasmodial activity.
AID285160Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1435653Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 7357/1998 after 14 days by micromethod2017European journal of medicinal chemistry, Jan-27, Volume: 126S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents.
AID1296386Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis Praha 1 after 14 days by microdilution method2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.
AID1904971Cytotoxicity against human HuH-7 cells assessed as reduction in cell viability incubated for 24 hrs by microplate reader assay2022European journal of medicinal chemistry, Apr-15, Volume: 234Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism.
AID1198527Plasma concentration in leprosy patient at 300 mg/kg, po dosed daily2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1224525Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 4 after 7 days by micromethod2014European journal of medicinal chemistry, Jul-23, Volume: 821-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria.
AID1198532Trypanocidal activity against GFP expressing Trypanosoma cruzi Y C57BL/6J mouse acute model of trypanosomal infection assessed as reduction in parasitemia at 20 mg/kg/day, ip measured at 10,14 and 20 days post infection2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID681127TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID707856Toxicity in BALB/c mouse infected with multi-drug resistant Mycobacterium tuberculosis isolate 040 assessed as skin discoloration at 20 mg/kg, po qd administered 5 days per week during acute phase of infection measured after 20 days2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.
AID1577335Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis 234/2005 after 14 days2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.
AID765269fT>MIC in Mycobacterium tuberculosis infected mouse2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1782218Antimycobacterial activity against Mycobacterium bovis BCG ATCC 35734 incubated for 5 days by broth dilution method2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Functionalized Dioxonaphthoimidazoliums: A Redox Cycling Chemotype with Potent Bactericidal Activities against
AID1224517Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 234/2005 after 7 days by micromethod2014European journal of medicinal chemistry, Jul-23, Volume: 821-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria.
AID1174922Antitubercular activity against Mycobacterium avium after 7 days by REMA resazurin microtiter assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.
AID1435650Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 131 after 14 days by micromethod2017European journal of medicinal chemistry, Jan-27, Volume: 126S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1176089Antileishmanial activity against Leishmania braziliensis MHOM/IT/2006/ISS2848 promastigotes assessed as inhibition of parasite growth after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Clofazimine analogs with antileishmanial and antiplasmodial activity.
AID1176095Selectivity index, ratio of IC50 for HMEC1 to IC50 for chloroquine-resistant Plasmodium falciparum W22015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Clofazimine analogs with antileishmanial and antiplasmodial activity.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1904968Cytotoxicity against golden hamster BSR cells assessed as reduction in cell viability incubated for 24 hrs by microplate luminometer method2022European journal of medicinal chemistry, Apr-15, Volume: 234Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1904975Binding affinity to SARS-CoV-2 spike protein assessed as Kd by SPR analysis2022European journal of medicinal chemistry, Apr-15, Volume: 234Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1678479Inhibition of recombinant His6-tagged SARS-CoV-2 main protease using Dabcyl-KTSAVLQ-SGFRKM-E(Edans-NH2) as substrate preincubated for 15 mins followed by substrate addition by FRET based assay2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
AID1463958Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate Praha 131 incubated for 14 days by micromethod2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents.
AID1296388Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis Praha 131 after 14 days by microdilution method2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.
AID707863Octanol-water partition coefficient, log P of the compound2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1176090Selectivity index, ratio of IC50 for HMEC1 to IC50 for Leishmania braziliensis MHOM/IT/2006/ISS28482015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Clofazimine analogs with antileishmanial and antiplasmodial activity.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1198507Inhibition of Trypanosoma cruzi cruzaine using mMBz-Pro-Phe-Arg-pNA substrate incubated for for 5 mins by UV-vis spectrophotometry2015European journal of medicinal chemistry, Mar-26, Volume: 93Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID1518985Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as effect on RR interval at 30 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection and measured at 2019European journal of medicinal chemistry, 12-15, Volume: 184Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1435648Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 1 after 14 days by micromethod2017European journal of medicinal chemistry, Jan-27, Volume: 126S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents.
AID707861Half life in BALB/c mouse at 20 mg/kg, po2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347150Optimization screen NINDS AMC qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347155Optimization screen NINDS Rhodamine qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,220)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990328 (26.89)18.7374
1990's248 (20.33)18.2507
2000's159 (13.03)29.6817
2010's333 (27.30)24.3611
2020's152 (12.46)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 69.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index69.50 (24.57)
Research Supply Index7.32 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index122.21 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (69.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials129 (9.37%)5.53%
Reviews126 (9.15%)6.00%
Case Studies296 (21.50%)4.05%
Observational12 (0.87%)0.25%
Other814 (59.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (37)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial [NCT03942354]Phase 2/Phase 354 participants (Anticipated)Interventional2019-09-01Recruiting
Effect of Additional Clofazimine on ENL Reactions in Leprosy [NCT01290744]Phase 4100 participants (Actual)Interventional2010-08-31Completed
Evaluating Newly Approved Drugs for Multidrug-resistant TB (endTB): A Clinical Trial [NCT02754765]Phase 3754 participants (Actual)Interventional2016-12-31Completed
STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB [NCT02409290]Phase 3588 participants (Actual)Interventional2016-03-31Completed
An Open-label Randomised Controlled Trial on Dual Therapy With Interferon Beta-1b and Clofazimine Combination, as Treatment for COVID-19 Infection [NCT04465695]Phase 281 participants (Anticipated)Interventional2020-07-14Recruiting
Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis [NCT03625739]800 participants (Anticipated)Observational [Patient Registry]2018-07-01Recruiting
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) [NCT03896685]Phase 3323 participants (Actual)Interventional2020-04-06Active, not recruiting
Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum [NCT00042289]1,578 participants (Actual)Observational2003-06-09Completed
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) [NCT04310930]Phase 2/Phase 3300 participants (Anticipated)Interventional2020-03-02Recruiting
Phase 2 Study of Clofazimine for the Treatment of Pulmonary Mycobacterium Avium Disease [NCT02968212]Phase 2102 participants (Anticipated)Interventional2017-04-11Recruiting
Study of RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Disease in Adults With Nodular Bronchiectasis (CleaR-MAC Trial) [NCT04616924]Phase 3125 participants (Anticipated)Interventional2020-12-01Active, not recruiting
Pharmacokinetics and Pharmacodynamics Sub-study for TB-PRACTECAL Clinical Trial ( PRACTECAL-PKPD) [NCT04081077]Phase 2/Phase 3240 participants (Anticipated)Interventional2019-08-06Active, not recruiting
A Randomised, Controlled, Open-Label, Phase II-III Trial to Evaluate the Safety and Efficacy of Regimens Containing Bedaquiline and Pretomanid for the Treatment of Adult Patients With Pulmonary Multidrug Resistant Tuberculosis [NCT02589782]Phase 2/Phase 3552 participants (Actual)Interventional2017-01-31Active, not recruiting
Independent Study to Establish the Efficacy of the Six Doses Uniform MDT Regimen (U-MDT) for Leprosy Patients [NCT00669643]Phase 4859 participants (Actual)Interventional2007-02-28Completed
Clofazamine in the Long Term Treatment of Leprosy, Phase III [NCT00852345]0 participants Expanded AccessNo longer available
An Open-Label, Randomized Trial of Four Treatment Regimens for Patients With Disseminated Mycobacterium Avium Complex Disease and Acquired Immunodeficiency Syndrome (AIDS) [NCT00001047]Phase 3400 participants InterventionalCompleted
A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study [NCT04311502]Phase 2104 participants (Actual)Interventional2021-06-16Active, not recruiting
Economic Evaluation of New MDR TB Regimens (PRACTECAL EE) [NCT04207112]Phase 2/Phase 3200 participants (Anticipated)Interventional2020-10-20Recruiting
Pharmacokinetic Study With a Loading Dose of Clofazimine in Adult Patients With Nontuberculous Mycobacterial Disease [NCT05294146]Phase 212 participants (Actual)Interventional2022-02-14Completed
An Open Label Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects With Active Crohn's Disease Despite 26 Weeks of Participation in the MAP US RHB-104-01 Study [NCT03009396]Phase 354 participants (Actual)Interventional2017-03-18Completed
Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis [NCT00513552]Phase 40 participants (Actual)Interventional2007-07-31Withdrawn(stopped due to No patient)
A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease [NCT00002058]0 participants InterventionalCompleted
Novartis Multiple Patient Program for Lamprene® (Clofazimine) for the Treatment of Non-Tuberculous Mycobacterial (NTM) Infections [NCT04334070]0 participants Expanded AccessAvailable
A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals. [NCT00000641]Phase 290 participants InterventionalCompleted
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of Clofazimine (CFZ) in Cryptosporidiosis [NCT03341767]Phase 233 participants (Actual)Interventional2017-12-14Terminated(stopped due to Insufficient accrual rate)
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T) (TB-TRUST)-PLUS [NCT04717908]89 participants (Actual)Interventional2021-01-20Active, not recruiting
Natural History, Genetics, Phenotype, and Treatment of Mycobacterial Infections [NCT00018044]1,000 participants (Anticipated)Observational2001-01-01Recruiting
A Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of the Following: TMC207 Plus PA-824 Plus Pyrazinamide Plus Clofazimine, TMC207 Plus PA-824 Plus Pyrazinamide, TMC207 Plus PA-824 Plus Clofazimine Alone, TMC207 Plus Pyra [NCT01691534]Phase 2105 participants (Actual)Interventional2012-10-31Completed
A Randomized Open-Label Study of the Tolerability and Efficacy of Clarithromycin and Ethambutol in Combination With or Without Clofazimine for the Treatment of Disseminated MAC (dMAC) in Patients With AIDS [NCT00002331]0 participants Interventional1994-01-31Completed
Prospective, Randomized, Partially Blinded, Phase 2 Study of the Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB [NCT03828201]Phase 2220 participants (Anticipated)Interventional2022-06-07Recruiting
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in [NCT00000796]525 participants InterventionalCompleted
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis [NCT03474198]Phase 2/Phase 3675 participants (Actual)Interventional2018-03-21Completed
An Open Label, Randomized Controlled Trial to Establish the Efficacy and Safety of a Study Strategy Consisting of 6 Months of Bedaquiline (BDQ), Delamanid (DLM), and Linezolid (LNZ), With Levofloxacin (LVX) and Clofazimine (CFZ) Compared to the Current So [NCT04062201]Phase 3402 participants (Actual)Interventional2019-08-22Active, not recruiting
A Multicenter, Randomized, Open-Label Study To Evaluate The Efficacy And Safety Of A Contezolid, Delamanid and Bedaquiline-Containing Short Regimen For The Treatment Of Rifampicin-Resistant Pulmonary Tuberculosis [NCT06081361]Phase 3186 participants (Anticipated)Interventional2023-11-01Not yet recruiting
A Phase II, Prospective, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety/Tolerability of Two Linezolid Dosing Strategies in Combination With a Short Course Regimen for the Treatment of Drug-Resistant Pulmonary Tuberculosis [NCT05007821]Phase 2132 participants (Anticipated)Interventional2022-08-11Recruiting
A Pragmatic Randomized Controlled Trial to Evaluate the Efficacy and Safety of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Patients With Multidrug-resistant Tuberculosis in China [NCT05306223]Phase 4212 participants (Anticipated)Interventional2022-05-10Recruiting
A Phase IIc, Open-Label, Randomized Controlled Trial of Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis (PRESCIENT) [NCT05556746]Phase 2156 participants (Anticipated)Interventional2023-10-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00042289 (26) [back to overview]Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]Plasma Concentration for Contraceptives
NCT00042289 (26) [back to overview]Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT01691534 (6) [back to overview]Early Bactericidal Activity (EBA) Measured as the Daily Rate of Change in log10 CFUs (Colony Forming Units) of M. Tuberculosis in Sputum on Solid Media (Days 0-14).
NCT01691534 (6) [back to overview]EBA Measured as the Daily Rate of Change in log10 CFUs of M. Tuberculosis in Sputum on Solid Media (Days 7-14)
NCT01691534 (6) [back to overview]EBA Expressed as the Daily Percentage Change in Time to Positive (TTP) Signal in Liquid Culture for M. Tuberculosis (Days 0-14)
NCT01691534 (6) [back to overview]EBA Expressed as the Daily Percentage Change in TTP Signal in Liquid Culture for M. Tuberculosis (Day 0-2)
NCT01691534 (6) [back to overview]EBA Expressed as the Daily Percentage Change in TTP Signal in Liquid Culture for M. Tuberculosis (Days 7-14)
NCT01691534 (6) [back to overview]EBA Measured as the Daily Rate of Change in log10 CFUs of M. Tuberculosis in Sputum on Solid Media (Days 0-2)
NCT02409290 (5) [back to overview]Failure or Recurrence (FoR)
NCT02409290 (5) [back to overview]Favourable Outcome After Long-term Follow-up (132 Weeks)
NCT02409290 (5) [back to overview]Proportion of Patients With Acquired Drug Resistance
NCT02409290 (5) [back to overview]STREAM Stage 2 Primary Outcome Measure (the Proportion of Patients With a Favourable Outcome at Week 76)
NCT02409290 (5) [back to overview]Failure or Recurrence (FoR)
NCT03009396 (8) [back to overview]Durable Remission Week 16 Through Week 52
NCT03009396 (8) [back to overview]Increase in Milliseconds (ms) QT Wave
NCT03009396 (8) [back to overview]Number of Patients in Remission at Week 16
NCT03009396 (8) [back to overview]Number of Weeks the Patients Are in Response.
NCT03009396 (8) [back to overview]Number of Weeks to Achieve Response
NCT03009396 (8) [back to overview]Response at Week 16
NCT03009396 (8) [back to overview]The Number of Weeks for Patients to Achieve Remission
NCT03009396 (8) [back to overview]Number of Weeks the Patients Are in Remission

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs

Infant plasma concentrations were collected and measured during the first 9 days of life. Half-life is defined as 0.693/k, where k, the elimination rate constant, is the slope of the decline in concentrations. (NCT00042289)
Timeframe: Infant plasma samples at 2-10, 18-28, 36-72 hours and 5-9 days after birth.

Interventionhour (Median)
DTG 50mg q.d.32.8
EVG/COBI 150/150mg q.d.7.6
DRV/COBI 800/150 mg q.d.NA
EFV 600 mg q.d. (Outside THA)65.6

[back to top]

PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.

,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.2.842.524.51
DRV/RTV 600/100mg b.i.d.2.122.222.51
FPV/RTV 700/100mg b.i.d.2.121.642.87
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA0.470.52

[back to top]

PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.

,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ETR 200mg b.i.d.0.360.480.38
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)0.130.130.28
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.3.75.17.2
RAL 400mg b.i.d.0.06210.0640.0797

[back to top]

PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs

"Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose.~For the TAF 25 mg q.d., 10 mg q.d. w/COBI, and 25 mg q.d. w/COBI or RTV boosting arms, samples were all below the limit of quantification and statistical analyses were not conducted." (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.

,,,,,,,,,,,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ATV/COBI 300/150 mg q.d.0.210.210.61
ATV/RTV Arm 1: 300/100mg q.d.2.00.71.2
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.0.490.710.90
DRV/COBI 800/150 mg q.d.0.330.271.43
DRV/RTV 800/100mg q.d.0.991.172.78
DTG 50mg q.d.0.730.931.28
EFV 600 mg q.d. (Outside THA)1.491.481.94
EVG/COBI 150/150mg q.d.0.02580.04870.3771
TAF 10mg q.d. w/COBI0.001950.001950.00195
TAF 25mg q.d.0.001950.001950.00195
TAF 25mg q.d. w/COBI or RTV Boosting0.001950.001950.00195
TFV 300mg q.d.0.0390.0540.061
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.0.30.50.8
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.0.440.571.26

[back to top]

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.

Interventionmg/L (Median)
3rd TrimesterPostpartum
EFV 600mg q.d.1.602.05

[back to top]

Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8, 12, and 24 hours post dosing.

,
Interventionmcg*hr/mL (Median)
Before contraceptive initiationAfter contraceptive initiation
ATV/RTV/TFV 300/100/300mg q.d. With ENG53.9655.25
EFV 600mg q.d. With ENG53.6456.65

[back to top]

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs

Cord blood and maternal plasma concentrations were collected and measured at delivery, and compared as a ratio. (NCT00042289)
Timeframe: Measured at time of delivery with single cord blood and single maternal plasma sample.

Interventionunitless (Median)
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.0.15
DTG 50mg q.d.1.25
EVG/COBI 150/150mg q.d.0.91
DRV/COBI 800/150 mg q.d.0.07
ATV/COBI 300/150 mg q.d.0.07
TFV 300mg q.d.0.88

[back to top]

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs

Cord blood and maternal plasma concentrations were collected and measured at delivery, and compared as a ratio. For arms with zero overall participants analyzed, samples were below the limit of quantification and ratios could not be calculated. (NCT00042289)
Timeframe: Measured at time of delivery with single cord blood and single maternal plasma sample.

Interventionunitless (Median)
TAF 10mg q.d. w/COBI0.97
EFV 600 mg q.d. (Outside THA)0.67
EFV 600mg q.d.0.49
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.0.2
RAL 400mg b.i.d.1.5
ETR 200mg b.i.d.0.52
MVC 150 or 300mg b.i.d.0.33
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.0.14
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.0.16
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.0.19
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)0.12
RPV 25mg q.d.0.55
ATV/RTV 300/100mg q.d. or TFV/ATV/RTV 300/300/100mg q.d.0.18
DRV/RTV 800/100mg q.d. or DRV/RTV 600/100mg b.i.d.0.18

[back to top]

Plasma Concentration for Contraceptives

Serum concentrations of the contraceptives. Note that no historical controls were provided by team pharmacologists and thus no comparisons were done for contraceptive concentrations in women using hormonal contraceptives and selected ARV drugs as compared to historical controls not using those ARV drugs. (NCT00042289)
Timeframe: Measured at 6-7 weeks after contraceptive initiation postpartum

Interventionpg/mL (Median)
ATV/RTV/TFV 300/100/300mg q.d. With ENG604
LPV/RTV 400/100 b.i.d. With ENG428
EFV 600mg q.d. With ENG125

[back to top]

Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12h (area-under-the-curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8 and 12 hours post dosing.

Interventionmcg*hr/mL (Median)
Before contraceptive initiationAfter contraceptive initiation
LPV/RTV 400/100 b.i.d. With ENG115.97100.20

[back to top]

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.

Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
RPV 25mg q.d.0.0630.0560.081

[back to top]

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC (area under the curve) were determined using the linear trapezoidal rule. See PK target in the Protocol Appendix V. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.

,
InterventionParticipants (Count of Participants)
3rd TrimesterPostpartum
EFV 600mg q.d.2021
MVC 150 or 300mg b.i.d.87

[back to top]

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC (area under the curve) were determined using the linear trapezoidal rule. See PK target in the Protocol Appendix V. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.

,,,,,,,,,,,,,,,,,,,,,,
InterventionParticipants (Count of Participants)
2nd Trimester3rd TrimesterPostpartum
ATV/RTV Arm 1: 300/100mg q.d.11212
DRV/COBI 800/150 mg q.d.3414
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.71622
DRV/RTV 600/100mg b.i.d.71922
DRV/RTV 800/100mg q.d.91922
DTG 50mg q.d.92023
EFV 600 mg q.d. (Outside THA)123334
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.82927
ETR 200mg b.i.d.5137
EVG/COBI 150/150mg q.d.81018
FPV/RTV 700/100mg b.i.d.82622
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)101926
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.93027
ATV/COBI 300/150 mg q.d.125
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA1514
RAL 400mg b.i.d.113330
RPV 25mg q.d.142625
TAF 10mg q.d. w/COBI152322
TAF 25mg q.d.132324
TAF 25mg q.d. w/COBI or RTV Boosting102418
TFV 300mg q.d.22727
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.11112
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.72332

[back to top]

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs

Infant plasma concentrations were collected and measured during the first 9 days of life. (NCT00042289)
Timeframe: Blood samples were collected at 2-10, 18-28, 36-72 hours and 5-9 days after birth.

,,,
Interventionmcg/mL (Median)
2-10 hours after birth18-28 hours after birth36-72 hours after birth5-9 days after birth
DRV/COBI 800/150 mg q.d.0.351.431.871.72
DTG 50mg q.d.1.731.531.000.06
EFV 600 mg q.d. (Outside THA)1.11.00.90.4
EVG/COBI 150/150mg q.d.0.1320.0320.0050.005

[back to top]

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs

Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

Interventionng*hour/mL (Geometric Mean)
2nd Trimester3rd TrimesterPostpartum
MVC 150 or 300mg b.i.d.NA27173645

[back to top]

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12 (area under the curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

,,,
Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.55.151.879.6
DRV/RTV 600/100mg b.i.d.45.845.961.7
FPV/RTV 700/100mg b.i.d.43.5032.1551.60
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA34.233.5

[back to top]

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12 (area under the curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

,,,
Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
ETR 200mg b.i.d.4.58.35.3
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)14.916.127.1
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.7296133
RAL 400mg b.i.d.6.65.411.6

[back to top]

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24 (area under the curve from 0 to 24 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.

,,,,,,,,,,,,,
Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
ATV/COBI 300/150 mg q.d.25.3318.8536.20
ATV/RTV Arm 1: 300/100mg q.d.88.241.957.9
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.30.645.748.8
DRV/COBI 800/150 mg q.d.50.0042.0595.55
DRV/RTV 800/100mg q.d.64.663.5103.9
DTG 50mg q.d.47.649.265.0
EFV 600 mg q.d. (Outside THA)47.3060.0262.70
EVG/COBI 150/150mg q.d.15.314.021.0
TAF 10mg q.d. w/COBI0.1970.2060.216
TAF 25mg q.d.0.1710.2120.271
TAF 25mg q.d. w/COBI or RTV Boosting0.1810.2570.283
TFV 300mg q.d.1.92.43.0
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.14.528.839.6
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.26.237.758.7

[back to top]

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.

Interventionmg*hour/L (Median)
3rd TrimesterPostpartum
EFV 600mg q.d.55.458.3

[back to top]

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.

Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
RPV 25mg q.d.1.9691.6692.387

[back to top]

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

Interventionmg/L (Median)
3rd TrimesterPostpartum
EFV 600mg q.d.5.445.10

[back to top]

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

,,,,,,,,,,,,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ATV/COBI 300/150 mg q.d.2.822.203.90
ATV/RTV Arm 1: 300/100mg q.d.NA3.64.1
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.3.114.514.52
DRV/COBI 800/150 mg q.d.4.593.677.04
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.6.226.558.96
DRV/RTV 600/100mg b.i.d.5.645.537.78
DRV/RTV 800/100mg q.d.6.775.788.11
DTG 50mg q.d.3.623.544.85
EFV 600 mg q.d. (Outside THA)3.875.134.41
FPV/RTV 700/100mg b.i.d.5.615.126.75
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)3.893.625.37
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA5.15.0
TFV 300mg q.d.0.2500.2450.298
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.1.22.54.1
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.2.733.565.43

[back to top]

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ETR 200mg b.i.d.0.701.010.63
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.8.410.714.6
RAL 400mg b.i.d.2.2501.7703.035
RPV 25mg q.d.0.1450.1340.134

[back to top]

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

Interventionng/mL (Median)
3rd TrimesterPostpartum
MVC 150 or 300mg b.i.d.448647

[back to top]

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

,,,
Interventionng/mL (Median)
2nd Trimester3rd TrimesterPostpartum
EVG/COBI 150/150mg q.d.1447.11432.81713.1
TAF 10mg q.d. w/COBI80.491.298.2
TAF 25mg q.d.69.796133
TAF 25mg q.d. w/COBI or RTV Boosting87.8107141

[back to top]

PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 12 hrs after an observed dose.

Interventionng/mL (Geometric Mean)
3rd TrimesterPostpartum
MVC 150 or 300mg b.i.d.108128

[back to top]

Early Bactericidal Activity (EBA) Measured as the Daily Rate of Change in log10 CFUs (Colony Forming Units) of M. Tuberculosis in Sputum on Solid Media (Days 0-14).

(NCT01691534)
Timeframe: 14 consecutive days of treatment

Interventionlog10CFU/ml/day (Mean)
TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C)0.115
TMC207, PA-824 and Pyrazinamide (J-PA-Z)0.167
TMC207, PA-824 and Clofazimine (J-PA-C)0.076
TMC207, Pyrazinamide and Clofazimine (J-Z-C)0.124
Pyrazinamide (Z)0.036
Clofazimine (C)-0.017
Rifafour0.151

[back to top]

EBA Measured as the Daily Rate of Change in log10 CFUs of M. Tuberculosis in Sputum on Solid Media (Days 7-14)

(NCT01691534)
Timeframe: Day 7-14

Interventionlog10CFU/ml/day (Mean)
TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C)0.085
TMC207, PA-824 and Pyrazinamide (J-PA-Z)0.146
TMC207, PA-824 and Clofazimine (J-PA-C)0.085
TMC207, Pyrazinamide and Clofazimine (J-Z-C)0.118
Pyrazinamide (Z)0.022
Clofazimine (C)-0.038
Rifafour0.157

[back to top]

EBA Expressed as the Daily Percentage Change in Time to Positive (TTP) Signal in Liquid Culture for M. Tuberculosis (Days 0-14)

(NCT01691534)
Timeframe: Days 0-14

Interventionpercentage of change in time/day (Mean)
TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C)6.3
TMC207, PA-824 and Pyrazinamide (J-PA-Z)7.0
TMC207, PA-824 and Clofazimine (J-PA-C)4.3
TMC207, Pyrazinamide and Clofazimine (J-Z-C)4.9
Pyrazinamide (Z)2.0
Clofazimine (C)-0.3
Rifafour6.3

[back to top]

EBA Expressed as the Daily Percentage Change in TTP Signal in Liquid Culture for M. Tuberculosis (Day 0-2)

(NCT01691534)
Timeframe: Day 0-2

Interventionpercentage of change in time/day (Mean)
TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C)10.6
TMC207, PA-824 and Pyrazinamide (J-PA-Z)13.2
TMC207, PA-824 and Clofazimine (J-PA-C)6.0
TMC207, Pyrazinamide and Clofazimine (J-Z-C)9.1
Pyrazinamide (Z)4.7
Clofazimine (C)2.1
Rifafour12.9

[back to top]

EBA Expressed as the Daily Percentage Change in TTP Signal in Liquid Culture for M. Tuberculosis (Days 7-14)

(NCT01691534)
Timeframe: Days 7-14

Interventionpercentage of change in time/day (Mean)
TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C)3.6
TMC207, PA-824 and Pyrazinamide (J-PA-Z)4.5
TMC207, PA-824 and Clofazimine (J-PA-C)3.1
TMC207, Pyrazinamide and Clofazimine (J-Z-C)3.0
Pyrazinamide (Z)0.8
Clofazimine (C)-1.3
Rifafour4.4

[back to top]

EBA Measured as the Daily Rate of Change in log10 CFUs of M. Tuberculosis in Sputum on Solid Media (Days 0-2)

(NCT01691534)
Timeframe: Days 0-2

Interventionlog10CFU/ml/day (Mean)
TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C)0.161
TMC207, PA-824 and Pyrazinamide (J-PA-Z)0.196
TMC207, PA-824 and Clofazimine (J-PA-C)0.062
TMC207, Pyrazinamide and Clofazimine (J-Z-C)0.132
Pyrazinamide (Z)0.080
Clofazimine (C)0.018
Rifafour0.141

[back to top]

Failure or Recurrence (FoR)

The proportion of patients with failure or recurrence (FoR) (NCT02409290)
Timeframe: 132 weeks, control regimen (arm B) using concurrent controls only

InterventionParticipants (Count of Participants)
Regimen B (Control Regimen)14
Regimen D (6-month Regimen)2

[back to top]

Favourable Outcome After Long-term Follow-up (132 Weeks)

The proportion of patients with a favourable outcome at their last efficacy visit (NCT02409290)
Timeframe: Last efficacy visit, between 96 and 132 weeks

InterventionParticipants (Count of Participants)
Regimen A (Long Regimen)17
Regimen B (Control Regimen)126
Regimen C (Oral Regimen)152
Regimen D (6-month Regimen)115

[back to top]

Proportion of Patients With Acquired Drug Resistance

The proportion of patients with acquired drug resistance (any drug) (NCT02409290)
Timeframe: 132 weeks

InterventionParticipants (Count of Participants)
Regimen A (Long Regimen)0
Regimen B (Control Regimen)5
Regimen C (Oral Regimen)5
Regimen D (6-month Regimen)3

[back to top]

STREAM Stage 2 Primary Outcome Measure (the Proportion of Patients With a Favourable Outcome at Week 76)

The primary efficacy outcome of the STREAM Stage 2 comparison is status at Week 76 i.e. the proportion of patients with a favourable outcome at Week 76 (NCT02409290)
Timeframe: 76 weeks

InterventionParticipants (Count of Participants)
Regimen A (Long Regimen)0
Regimen B (Control Regimen)133
Regimen C (Oral Regimen)162
Regimen D (6-month Regimen)122

[back to top]

Failure or Recurrence (FoR)

probable or definite failure or recurrence (FoR) (NCT02409290)
Timeframe: final efficacy week (between 96 and 132 weeks)

InterventionParticipants (Count of Participants)
Regimen A (Long Regimen)0
Regimen B (Control Regimen)17
Regimen C (Oral Regimen)4
Regimen D (6-month Regimen)0

[back to top]

Durable Remission Week 16 Through Week 52

When a subject is in remission with a maximum CDAI score of 149 at every visit from week 16 through and including week 52. (NCT03009396)
Timeframe: Week 16 through week 52

InterventionParticipants (Count of Participants)
RHB-104 From ACTIVE Arm of RHB-104-011
RHB-104 From PLACEBO Arm of RHB-104-017

[back to top]

Increase in Milliseconds (ms) QT Wave

The increase in the number of milliseconds change-from-baseline to week 52 in QTcF (Fridericia's Correction Formula of QT wave interval) (based on cardiac safety report). (NCT03009396)
Timeframe: week 52

Interventionms (Least Squares Mean)
RHB-104 From ACTIVE Arm of RHB-104-0123.9
RHB-104 From PLACEBO Arm of RHB-104-0127.6

[back to top]

Number of Patients in Remission at Week 16

"The number of patients who achieved a reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150 points.~Lower CDAI scores indicate a better outcome." (NCT03009396)
Timeframe: Week 16

InterventionParticipants (Count of Participants)
RHB-104 From ACTIVE Arm of RHB-104-013
RHB-104 From PLACEBO Arm of RHB-104-0114

[back to top]

Number of Weeks the Patients Are in Response.

Duration of response is defined as the number of weeks the subject is in a state of response (a reduction from baseline of ≥ 100 in CDAI score). It is calculated as the first date following response at which the reduction from baseline in CDAI is <100 minus the date of first response, plus 1 day, divided by 7. Subjects who experienced response and continued to be in response at the time of their last CDAI assessment are censored at the date of their last CDAI assessment. (NCT03009396)
Timeframe: Baseline through week 52

InterventionWeeks (Median)
RHB-104 From ACTIVE Arm of RHB-104-0129.4
RHB-104 From PLACEBO Arm of RHB-104-0145.0

[back to top]

Number of Weeks to Achieve Response

[Date of first observed response (a reduction from baseline of ≥ 100 in CDAI score) - Date of first dose or date of randomization if not dosed + 1] / 7 Days. Subjects who never experienced response during the study are censored at the date of their last CDAI assessment. (NCT03009396)
Timeframe: Baseline through week 52

InterventionWeeks (Median)
RHB-104 From ACTIVE Arm of RHB-104-01NA
RHB-104 From PLACEBO Arm of RHB-104-0126.1

[back to top]

Response at Week 16

Reduction of the total Crohn's Disease Activity Index (CDAI) score by a minimum of 100 points Lower CDAI scores indicate a better outcome. (NCT03009396)
Timeframe: Week 16

InterventionParticipants (Count of Participants)
RHB-104 From ACTIVE Arm of RHB-104-014
RHB-104 From PLACEBO Arm of RHB-104-0114

[back to top]

The Number of Weeks for Patients to Achieve Remission

[Date of first observed remission (CDAI less than 150) - date of first dose, or date of randomization if not dosed, plus 1] / 7 days. Subject who never experience remission during the study are censored at the time of their last CDAI assessment. (NCT03009396)
Timeframe: Baseline through week 52

Interventionweeks (Median)
RHB-104 From ACTIVE Arm of RHB-104-01NA
RHB-104 From PLACEBO Arm of RHB-104-0125.1

[back to top]

Number of Weeks the Patients Are in Remission

Duration of remission is defined as the number of weeks the subject is in remission (CDAI score < 150). It is calculated as the first date following remission at which CDAI is ≥150 minus the date of first remission, plus 1 day, divided by 7. Subjects who experienced remission and continued to be in remission at the time of their last CDAI assessment are censored at the date of their last CDAI assessment. (NCT03009396)
Timeframe: Baseline through week 52

Interventionweeks (Median)
RHB-104 From ACTIVE Arm of RHB-104-0111.7
RHB-104 From PLACEBO Arm of RHB-104-0145.0

[back to top]